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 Repair after injury to the adult mammalian central nervous system (CNS) 
is hindered by inhibitory proteins, including the myelin associated inhibitors 
(MAIs):  NogoA, MAG, and OMgp.  Blocking the function of MAIs and their 
receptors enhances axon regrowth following injury. These findings suggest that 
therapeutic control of these inhibitors may be a strategy for regulating axon 
outgrowth and plasticity, leading to restoration of neuronal connections lost in 
response to injury or disease. Thus, functional recovery after CNS injury is 
limited by MAIs, and small molecule compounds that can circumvent MAI 
inhibition are likely to enhance functional recovery after stroke or spinal cord 
injury. 
The precise intracellular molecular signaling mechanisms of MAIs are not 
well understood. Toward this goal, it is demonstrated here that the multi-domain 
scaffold protein POSH assembles a distinct signaling module composed of the 
mixed-lineage kinase LZK, the actin-myosin regulatory protein Shroom3, and 
Rho-associated kinase, ROCK. Through the receptor PirB, the POSH complex 
mediates growth inhibitory signals from extracellular NogoA and MAG, as well as 
cell autonomous NogoA signaling.  PirB associates with the protein tyrosine 
phosphatase, Shp2, and we show that phosphatase activity of Shp2 is required 
for axonal growth inhibition. In addition, NogoA stimulation promotes trapping of 
LZK with Shp2, suggesting LZK is a potential substrate for dephosphorylation by 
Shp2.  
 Lastly, interference with the function of any member of the POSH 
complex results in enhanced growth on MAIs, suggesting that chemicals that 
target protein-protein interactions within the POSH complex will reduce the 
inhibitory action of MAIs, facilitating axon outgrowth in the CNS. Towards this 
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goal, high-throughput screening in the Center for Chemical Genomics at the 
University of Michigan has identified potential inhibitors of the Shroom3-ROCK 
interaction. Collectively, these studies delineate an intracellular signaling 
pathway emanating from MAIs through the receptor PirB to the POSH complex. 
Further insight into the molecular signaling mechanisms of this pathway may 








1.1  Development and wiring of the nervous system 
 
The mammalian nervous system with its billions of nerve cells and 
unimaginably complex network of nerve fibers and connections is unlike any 
other organ in the body. During embryogenesis, the brain generates 50-100 
thousand new cells per second derived from the neural tube [1]. Newborn 
neurons migrate to their designated destinations where they mature, projecting 
axons and dendrites to form neuronal connections. The correct formation of 
neuronal connections is crucial for higher order function of the nervous system; 
therefore nature has developed an extensive and complex system to mediate 
axonal growth and pathfinding.  
The nervous system is patterned with molecular guidance cues which 
create a road map for developing axons, leading them to their synaptic targets 
(Figure 1.1). Guidance molecules can be located on the cell surface of 
neighboring neuronal or glial cells or secreted into the extracellular space acting 
as chemical signals [2]. These cues can be either repulsive or attractive and 
function as short-range or long-range signals. Moreover, some guidance cues 
are bifunctional, being attractive to some axons and repulsive to others [2, 3]. 
The semaphorins, which are a large family of both secreted and membrane-
associated proteins, are an excellent example of bifunctional guidance cues. 
Members of the semaphorin family are capable of mediating both repulsive and 
attractive guidance events in the developing nervous system and it is believed 







Guidance molecules influence axonal growth through modulating 
cytoskeleton dynamics, which is made up of actin, microtubule, or myosin 
molecules. Each axon extended by a differentiated neuron contains a growth 
cone at its leading edge. The growth cone detects molecular guidance cues and 
signaling events at the growth cone mediate the appropriate response. For 
example, inhibitory signals can cause the growth cone to collapse, facilitating 
axon retraction [2-4].  
 
1.2 Plasticity of the nervous system 
 
After the establishment and refinement of the nervous system during 
embryonic and early post-natal periods, the mammalian central nervous system 
undergoes stabilization, moving away from being highly fluidic towards a more 
structured environment to maintain neuronal connections [5]. Synaptic 
remodeling and dendritic pruning occurs to allow for learning and functional 
adaptation.  However, long distance changes in axon length, greater than several 
millimeters or more, are rarely seen [6]. The umbrella term “neuronal plasticity” is 
used to define changes that culminate in rewiring or reorganization of neuronal 
networks. Examples of plastic changes include: synaptic remodeling and axonal 
sprouting leads to new neuronal connections [7].  
Extensive research has gone into determining the intrinsic and extrinsic 
differences in gene expression, protein localization, and the extracellular 
environment responsible for the shift from rapid growth and re-arrangement to a 
more conservative structure and plasticity [5, 8, 9]. It is now known that intrinsic 
neuronal growth potential decreases as neurons mature and one hypothesis for 
this phenomenon is down-regulation of growth-promoting genes. Additionally, 
select guidance cues that influenced axonal pathfinding persist into adulthood, 
maintaining connections and directing secondary branching of axons and 
dendrites. There are also additional proteins that are expressed in the mature 
CNS which regulate neuronal plasticity [5, 8, 9]. Therefore, it may be more 
correct to refer to these molecules as “guidance cues” during development and 
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“regulatory cues” in adulthood.  Regardless, the understanding of the function of 
regulatory cues throughout all stages of life provides a valuable tool and is 
particularly relevant for the development of therapeutic strategies to promote 
regeneration of damaged neuronal connections in the CNS after traumatic injury 
or disease.  
 
1.3  Lack of regeneration of the central nervous system after injury or 
disease 
 
Spontaneous and functionally relevant regeneration or replacement of lost 
neuronal tissue is limited and often absent following injury or disease of the CNS. 
In 1927, Ramon y Cajal was the first to observe that axons of the CNS fail to 
regenerate [10]. This is in stark contrast to the axons of the peripheral nervous 
system (PNS) whose axons regenerate after injury. Subsequently, Aguayo and 
colleagues demonstrated in a series of experiments that damaged CNS axons 
can regenerate if provided with a permissive substrate [11-13]. Sciatic nerve 
grafts were used as bridges between regions of the CNS, for example in a 
midthoracic spinal cord lesion and between the medulla oblongata and the upper 
thoracic spinal cord. They showed that transected axons from the adult rat CNS 
were able to grow into PNS tissue grafts to distances upwards of 1cm. 
Additionally, axon growth terminated at the edge of the graft where the CNS 
tissue resumed. These studies indicated that CNS neurons retain the intrinsic 
ability to regenerate when presented with the growth-permissive PNS 
environment. Conversely, PNS axons navigated around, not through CNS 
implants, suggesting the presence of inhibitory molecules in the CNS that both 
PNS and CNS neurons are responsive towards. This result was critical in 
establishing that CNS neurons retain the capability to grow and the lack of 
regeneration is due to the presence of inhibitory molecules and/or 
receptors/ligands, not present in the PNS. Working off this hypothesis, much 
effort began to identify CNS inhibitory molecules and characterize their 
mechanism of axon growth inhibition in the hope that manipulation of their activity 




1.4 The role of myelin and its associated proteins on axon outgrowth  
 
 A prominent difference between the embryonic brain and the adult brain is 
the presence of myelin, which is visualized as the white matter of the brain. In 
humans, myelination begins in late fetal development and proceeds, although 
slower, into adulthood [14]. The brain myelinates in a wave like fashion from the 
back of the head to the frontal lobe, which is the last portion of the brain to 
myelinate [1, 15]. The onset of myelination coincides with a decrease in neuronal 
plasticity [16]. However, development of white matter structure in children 
correlates with enhanced motor skills, reading ability, and cognitive development, 
suggesting the stabilization of the brain by myelination is necessary for higher 
order function [16].  
Myelin forms a layer called the myelin sheath around the axons of a 
subset of neurons (Figure 1.2A).  The sheath is a greatly extended and modified 
plasma membrane. Myelin membranes originate from oligodendrocytes in the 
CNS and the Schwann cells in the PNS [17].  The main purpose of the myelin 
sheath is to enhance the transmission of electrical impulses along the axon. The 
presence of myelin increases the speed at which the signal travels as well as 
insulates the axon preventing the loss of the electrical current [1, 15]. In the PNS, 
when an axon is severed the myelin sheath can function as a track along which 
regrowth can occur [18]. However, CNS myelin does not support regeneration. 
Martin E Schwab first demonstrated this by culturing neurons on dissociated 
CNS glial cells. Neurons were unable to extend axons on cultured 
oligodendrocytes or isolated myelin from the CNS, but were able to grow on 
myelin from the sciatic nerve of the PNS [19]. This and work by other groups 
indicated that one of the differences between the regenerative capacity of the 
PNS, versus the CNS, was due to extrinsic molecules present in myelin 
originating from oligodendrocytes. Consistent with this hypothesis, three 







growth in vitro: NogoA, myelin associated glycoprotein (MAG), and 




The inhibitory activity of NogoA was discovered by Martin E Schwab and 
colleagues over 20 years ago. First, extraction of myelin with 4M guanidinium 
chloride provided conditions that removed peripheral membrane proteins, and 
resulted in myelin that maintained a non-permissive growth environment for 
neurons in vitro. Second, lipid extraction resulted in a growth-permissive lipid 
fraction and a non-permissive protein fraction that had to be maintained in 
liposomes to function. Finally, trypsin treatment of CNS myelin removed axonal 
growth inhibition [20]. Collectively, these studies show that a membrane-bound 
protein is facilitating the non-permissive growth of myelin. Separation of myelin 
proteins by SDS-PAGE identified two proteins of 35 and 250kDa, termed NI-
35/250, that maintained a non-permissive substrate [20]. Removal of NI-35/250 
from CNS myelin resulted in a growth permissive substrate, while addition of NI-
35/250 to PNS membrane fractions caused a shift from permissive to non-
permissive. Antibodies developed against NI-250 allowed for the isolation of a 
cDNA encoding a protein that was growth inhibitory and was designated NogoA  
[21-24]. 
NogoA is a member of the Reticulon family, also known as Reticulon 4-A  
[23]. Reticulons are membrane bound proteins and are named due to their high 
expression on smooth endoplasmic reticulum [25]. In mammals there are four 
genes, rtn 1-4, encoding multiple splice variants of the reticulon proteins [26]. 
The reticulon proteins contain a conserved structural motif, called the reticulon 
homology domain (RHD), which contains a hydrophilic loop of 60-70 amino acids 
flanked by two putative transmembrane domains [27]. The three splice variants 
of the reticulon 4 gene, NogoA, NogoB, and NogoC, contain 188 amino acids in 
their C-terminus which correspond to the RHD. NogoA and NogoB share the first 
172 amino acids; however NogoA contains a unique 800 amino acids stretch in 
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between the N-terminus and the RHD. NogoC is made up of an extremely short 
N-terminus followed directly by the RHD [26, 27]. NogoA contains an 
endoplasmic reticulum retention motif, resulting in high ER expression and recent 
evidence suggests that NogoA may regulate the tubular morphology of the ER  
[28]. 
Three axonal growth inhibitory domains of NogoA have been identified. 
First, the loop between the two transmembrane domains, termed Nogo66, has 
been shown to be present on the extracellular surface of oligodendrocytes and 
has potent axon growth inhibitory effects in vitro [23, 29]. Nogo-66 binds to 
multiple receptors, including Nogo-66 receptor (NgR) and PirB (discussed in 
detail below) [30, 31]. The amino-terminal domain of NogoA contains a unique 
sequence called amino-Nogo that also inhibits axon outgrowth and the adhesion 
of non-neuronal cells; however the receptor mediating these actions has yet to 
be discovered [20, 29]. Amino-Nogo has been shown to bind and inhibit some 
integrin signaling, suggesting Amino-Nogo may inhibit axon growth through 
blocking growth-promoting integrin signaling [32]. A third, NogoA specific region, 
NiG-∆20, also strongly inhibits neurite outgrowth [29]. 
Attempts to determine the membrane topology of NogoA have proven 
difficult. Computer modeling predicts two transmembrane domains in the RHD, 
which are long enough (28-36 amino acids) to loop back through the membrane. 
Immunofluorescence studies have shown the most common topology in the ER 
places the N- and C-terminals in the cytoplasm. However, studies with antibodies 
against the N-terminus of NogoA and Nogo66 show that both regions are 
localized on the cell surface of oligodendrocytes [23, 33]. These studies indicate 
that the first transmembrane domain may adopt a flexible mechanism to either 
extend across the membrane or to flip back to adopt a horseshoe-like orientation. 
Additionally, NogoA, expressed intracellularly on the endoplasmic reticulum, may 
only be exposed when there is injury or death of the oligodendrocyte.  
NogoA is highly expressed on oligodendrocytes and only minimally on 
PNS Schwann cells consistent with a role in mediating axonal growth inhibition 
specifically in the CNS [34, 35]. On the oligodendrocyte surface, NogoA is 
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expressed on the innermost loop of myelin, where it could make contact with the 
axon (Figure 1.2). Interestingly, NogoA is also expressed in the neuron, albeit at 
lower levels. NogoA was found in the growth cone of growing olfactory bulb 
axons and in the projection neurons of the cortex and cerebellum [34-37]. In the 
developing forebrain cortex, NogoA expressing neurons migrate along NogoA 
positive radial glia and cells that will become part of the cortical plate pass 
between these NogoA expressing neurons. Interestingly, in NogoA knock-out 
mice, this migration is enhanced, while migration of cortical interneurons was 
delayed in NogoA deficient mice [38]. Additionally, removal of NogoA function in 
embryonic cortical neurons results in enhanced axonal branching in culture, while 
dorsal root ganglion neurons show increased fasciculation and decreased 
branching[39, 40]. Lastly, NogoA expressing radial glia in the ventral midline 
inhibit growing optic nerve axons and spinal cord commissural axons and 
blocking NogoA function leads to misprojected axons [41, 42]. Combined these 
studies suggest that NogoA can exert multiple guidance effects in the developing 
CNS in addition to its role as a myelin-associated inhibitory protein.  
 
1.4.2 Myelin-associated glycoprotein  
 
 Myelin-associated glycoprotein (MAG) was identified through purification 
and separation of molecules present in myelin. It is a potent inhibitor of neurite 
outgrowth and immunodepletion of MAG from CNS myelin allows for permissive 
growth [43, 44]. MAG is expressed by both CNS and PNS glial cells and has 
been shown to participate in the formation and maintenance of the myelin sheath  
[45]. It is highly expressed in myelin membranes adjacent to the axon. 
Interestingly, MAG is a bifunctional molecule and can regulate neurite outgrowth 
in an age-dependent manner. MAG promotes the growth of specific types of 
young neurons, while in the mature CNS MAG strongly inhibits neurite outgrowth 
[9, 46]. The molecular mechanism of the switch is unknown; however it appears 
to be dependent on the neuronal cell type and developmental stage. For 
example, late embryonic rat cortical neurons show a growth inhibitory response 
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toward MAG, while post-natal day 1 dorsal root ganglion neurons are able to 
extend processes on MAG [44, 47-49].  
MAG is a member of the immunoglobulin (Ig) super family and its 
extracellular domain contains five Ig domains [9]. It is also a sialic acid-binding 
protein with its first four Ig domains being homologous to those of other sialic 
acid-binding lectins. Following the Ig domains, MAG has a single transmembrane 
domain and a cytoplasmic domain. In rodents, MAG exists in two splice forms, L-
MAG and S-MAG, corresponding to variable cytoplasmic domain length [50]. To 
exert axon-inhibitory activity, MAG, like Nogo-66, interacts with the Nogo-66 
receptor and PirB [30, 51, 52]. It also interacts with Nogo receptor 2 (NgR2) [53, 
54]. The sialic acid binding activity of MAG is not required for neurite growth 
inhibition; however it has been observed that under certain conditions sialic acid 
binding can potentiate inhibitory signals[55]. 
  
1.4.3 Oligodendrocyte myelin glycoprotein 
 
A third myelin-associated protein, Oligodendrocyte myelin glycoprotein 
(OMgp), is a glycosylphosphatidylinositol (GPI)-linked protein that is expressed 
on oligodendrocytes, peripheral neurons, and in high levels on various CNS 
neurons [56, 57]. OMgp is a 110-kDa glycoprotein with five tandem leucine-rich 
repeats followed by a C-terminus with serine/threonine repeats. Similar to NogoA 
and MAG, OMgp expression induces growth cone collapse and inhibits neurite 
outgrowth[56]. The Nogo66 receptor and PirB both have been shown to bind 
OMgp to initiate signal transduction to inhibit axonal outgrowth [30, 58]. 
 
1.4.4 Additional inhibitory proteins in the CNS 
 
In addition to MAIs, there are other proteins present in the CNS that 
mediate growth-inhibitory effects.  Chrondroitin sulphate proteoglycans (CSPGs) 
are released by astrocytes at sites of CNS injury or disease along with other 
inhibitory extracellular matrix proteins[59]. CSPGs are potent inhibitors of axon 
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growth both in vitro and in vivo, and similar to MAG they have also been shown 
to promote growth in the correct cellular context. Canonical axon guidance 
molecules such as the semaphorin, netrin, and ephrin families are expressed 
through development and in the adult CNS. There is evidence that these proteins 
contribute to the inhibitory environment and upon injury the expression levels of 
these proteins often change [60-63]. For example, EphrinB3 is highly expressed 
in CNS myelin and is a potent inhibitor of neurite outgrowth in vitro, while 
Semaphorin 3A causes growth cone collapse. Through the identification of more 
and more inhibitory cues, it appears likely that robust regeneration of axon 
growth will require strategies that neutralize multiple inhibitory cues 
simultaneously, or a common downstream component. 
  
1.5  Receptors mediating myelin-associated growth inhibition 
 
There are several known receptors for MAIs and some receptors are able to 
associate with multiple MAIs. Additionally, several MAI receptors do not have 
intracellular domains, but rather require a co-receptor to relay signaling and 
depending on the neuronal cell type, the co-receptor can vary. A select group of 
receptors are described in greater detail below (Figure 1.2B).  
 
1.5.1 Nogo-66 receptor 1  
 
Nogo-66 receptor 1 (NgR1) was the first Nogo-66 receptor to be 
identified[31]. It is a GPI-linked leucine rich repeat protein that is expressed on 
the surface of neurons. Direct interaction of Nogo66 with NgR1 induces growth 
cone collapse, and transfection of Nogo66 unresponsive neurons with NgR1 
converts them to responsive [31]. NgR1 does not bind Amino-Nogo and blocking 
NgR function does not alleviate growth cone collapse induced with Amino-Nogo, 
suggesting the presence of an additional receptor for Amino-Nogo that has yet to 
be identified. There are multiple NgR family members in addition to NgR1, NgR2 
and NgR3.  The NgR family shares 55% identity in the leucine-rich repeat region; 
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however only NgR1 binds Nogo66. Interestingly, MAG and OMgp also bind 
NgR1, although MAG has been shown to bind NgR2 with greater affinity [51, 56]. 
 NgR1 does not have a transmembrane domain, and therefore it must 
associate with a co-receptor to mediate intracellular signaling (Figure 1.2B). The 
low affinity neurotrophin receptor p75 (p75NTR) interacts with NgR1 through its 
extracellular domain [64]. The intracellular domain of p75NTR is required for signal 
transduction as a truncated receptor is no longer able to activate the small 
GTPase, Rho, in a MAG dependent manner [64-66].  LINGO1 (LRR and Ig 
domain containing Nogo Receptor interacting protein) has also been identified as 
a component of the NgR1/ p75NTR complex [67]. The fact that p75NTR is 
detectable on only a subset of mature neurons led to the discovery that 
TAJ/TROY, an orphan tumor necrosis factor receptor family member can 
substitute for p75 as an alternative co-receptor for NgR1/LINGO1[68].  
 
1.5.2 Paired immunoglobulin-like receptor B (PirB) 
 
Paired immunoglobulin-like receptor B (PirB) is a receptor for all three 
MAIs: NogoA, MAG, and OMgp (Figure 1.2B) [30]. PirB was first described in the 
immune system [69, 70]. PirB is a MHC-1 class I receptor, contains a single 
transmembrane domain, and its intracellular domain has three potential 
immunoreceptor tyrosine based inhibitory motifs (ITIMs). Phosphorylation of 
these sites promotes the association of the protein tyrosine phosphatases, Shp1 
and Shp2 [71-73]. In immune cells, PirB acts as an inhibitory receptor and it is 
the recruitment of Shp1/Shp2 that leads to termination of signaling cascades 
initiated by activating receptors[74, 75]. In neurons, PirB has also been shown to 
associate with Shp2 through its intracellular domain, and this domain is crucial 
for relaying growth inhibition from myelin-associated proteins [30, 76]. 
Neutralization of PirB function by antibody treatment is sufficient to partially 
relieve growth inhibition by Nogo66 and myelin extracts and appears to be a 
more substantial mediator of MAI growth inhibition than NgR. Interestingly, 
studies with cerebellar granule neurons from NgR null mice suggest that the two 
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receptors work together to relay signals from myelin, but PirB is the more potent 
receptor of Nogo66 [30]. Recent studies have also shown that PirB together with 
p75 negatively regulate TrkB signaling to modulate axon outgrowth [77, 78]. 
Additionally, a transgenic mouse expressing a truncated form of PirB displays 
increased ocular-dominance plasticity suggesting that PirB acts as a negative 
regulator of neuronal stability/plasticity [30, 76]. Combined these studies define a 
role for PirB as a negative regulator of axon outgrowth in the CNS and also 
highlight the complexity of myelin-inhibitory events at the cellular surface of the 
neuron. 
 
1.6 From animal models to clinical trials: targeting MAIs for regeneration 
 
Myelin associated inhibitors are abundant in the adult mammalian central 
nervous system. They are expressed on the surface of oligodendrocytes, a 
subset of neurons, and are released after injury to limit axon outgrowth and 
plasticity. Much work has gone into the identification of MAIs and characterization 
of their inhibitory mechanism in cell culture. However, even though in vitro neurite 
growth assays are a powerful tool for studying inhibitory mechanisms, studies in 
animal models allow researchers to evaluate the significance and relative 
contribution of individual inhibitor molecules to regenerative failure in vivo.  
Several knock-out animals have been engineered looking at functional 
recovery after CNS injury following removal of inhibitory proteins. Three separate 
laboratories generated Nogo knockouts. However, only two saw enhanced 
sprouting and axonal regeneration after spinal cord injury (SCI), while the third 
group did not observe any difference in regeneration in Nogo knockout animals 
after SCI [79-81]. It was found that differences in the genetic background of the 
mice played a role in the conflicting results as Nogo-A knockout animals 
generated in two different pure background strains confirmed the initial results, 
enhanced regenerative fiber growth[82]. Interestingly, studies looking at 
regeneration in p75, NgR, and PirB knockout animals did not see enhanced 
growth after SCI, although there was some mild sprouting[83-86]. These studies 
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highlight the redundancy of MAI receptors in the CNS, indicating that simply 
targeting one inhibitory molecule will not be sufficient to promote robust and 
functional regeneration. 
 Antibody-based strategies, soluble function-blocking NgR ectodomain 
(NgR (310)-Fc), and an NgR1 antagonistic peptide (NEP1-40) have been 
successful in achieving anatomical and functional recovery following CNS injury 
[87-89]. The antibody IN-1 binds NogoA and inhibits NogoA function and delivery 
of IN-1 via implanted hybridoma cells into rats that had undergone a unilateral 
stroke, induced branching of the intact axons and the establishment of 
compensatory circuits. This resulted in an improvement in fine motor movement 
of paw which was lost due to stroke injury [90-92]. Treatment with IN-1 antibody 
in adult rats that had undergone spinal cord injury resulted in several millimeters 
of regrowth of the injured axon. Application of peptides blocking NgR function 
also promoted growth after injury. Studies in macaque monkeys that had been 
subjected to a unilateral spinal cord transection showed recovery of hand 
function [6, 93, 94]. Due to these promising results, a human anti-human NogoA 
antibody (ATI 355) has entered into clinical trials both in Europe and in North 
America. Phase I clinical trials have progressed positively and Phase II clinical 
trials began in 2010 to test the efficacy of the antibody on spinal cord treatment in 
acute paraplegic and tetraplegic patients [6].  
 
1.7 Decline of intrinsic growth-promoting signals in the adult CNS also 
contributes to the lack of regeneration after injury 
 
Much effort has gone into the identification and characterization of extrinsic 
inhibitory proteins in the CNS. As described previously, inhibition of MAIs and 
other inhibitory cues can lead to functional regeneration after injury or disease. 
However, there are additional factors blocking regeneration. It has become clear 
that neurons in the adult CNS display a decreased intrinsic ability to regenerate 
when compared to embryonic neurons. For example, cerebellar slices taken from 
post-natal day 10 rats survive in cell culture and maintain cellular composition 
resembling the mature cerebellum. Mature Purkinje cell axons do not regenerate 
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after axotomy even when provided with permissive substrates from the sciatic 
nerve or embryonic slices. However, embryonic Purkinje cells readily regenerate 
after axotomy and extend axons robustly into adult cerebellar slices [95, 96]. 
Similar developmental declines have been observed with retinal ganglion cells 
and tissue explants from the brainstem [97, 98]. In addition, some embryonic 
neurons, such as dorsal root ganglion (DRG) neurons, are able to grow on MAG, 
while DRGs isolated from postnatal mice are not [47, 99].  This has been 
observed for several of the myelin inhibitory cues and from these results, two 
hypotheses have arisen. First, that the expression of receptors for inhibitory 
ligands is lower in the embryonic versus the adult CNS, and secondly, that the 
adult CNS lacks the intrinsic growth properties of the embryonic CNS [100]. 
However, it is more likely that both hypotheses contribute to the lack of 
regeneration in the CNS, and therefore the molecular mechanism of the switch 
decreasing intrinsic growth properties in the adult CNS will need to be elucidated.  
To this end, roles for cyclic AMP and the PTEN/mTOR pathway have been 
implicated in the lack of intrinsic growth-promoting signals in the adult CNS. 
A direct correlation between cAMP levels and inhibition of neurite outgrowth 
by myelin and MAG was demonstrated. Intracellular cAMP levels are high in 
post-natal day 1 DRGs which are not inhibited by MAG or myelin. However, as 
the DRGs matured cAMP levels decreased, and the neurons became responsive 
to myelin inhibition [47].  Interestingly, a conditioning lesion on DRGs elevates 
cAMP levels and can relieve growth inhibition of MAIs [47, 100, 101]. The 
addition of pharmacological agents to elevate cAMP levels also relieves growth 
inhibition by MAIs. For example, injection of DRGs in vivo with a non-
hydrolyzable cAMP analogue induces regeneration of lesioned dorsal column 
axons[101]. The ability of cAMP to overcome MAI inhibition is protein kinase A 
(PKA) dependent and links to the activation of the transcription factor cAMP 
response element binding protein (CREB)[102]. Consistent with the initiation of 
transcription, several cAMP-regulated genes have been linked to MAIs and 
research is ongoing to determine the molecular mechanism of cAMP-mediated 
inhibition of MAIs. 
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Recently, it was shown that deletion of PTEN enhances survival of 
axotomized retinal ganglion cells and promotes regeneration of injured optic 
nerve fibers through the induction of sprouting, formation of new synapses, and 
regeneration of injured corticospinal tract axons[103, 104]. Loss of PTEN function 
leads to the activation of Akt and subsequently, mTOR, a critical regulator of 
protein translation initiation and cell growth [105]. It has been shown that mTOR 
signaling is downregulated in the mature CNS and axotomy further decreases 
mTOR activity [104]. mTOR is a critical regulator of protein translation initiation 
and cell growth. This suggests that the injured axon is further crippled by an 
inability to effectively synthesize new protein to promote regeneration[106].  
In summary, the lack of axonal regeneration in the CNS cannot only be 
attributed to the presence of extrinsic factors, such as myelin associated 
proteins. The loss of intrinsic growth capability of mature neurons also provides a 
large obstacle to promote regeneration in the injured CNS. Thus, these studies 
suggest that a dual approach, blocking MAI function and enhancing intrinsic 
neuronal growth, may be a more efficacious strategy to regenerate the injured 
CNS. 
 
1.8 Intracellular axon growth inhibitory signaling pathways 
  
 Due to the complexity and redundancy of inhibitory signals at the neuronal 
cell surface, it is advantageous to understand the intracellular signaling 
pathways, as a more potent therapeutic strategy to enhance axonal regeneration 
could be developed. Currently, there is a lack of knowledge of the molecular 
mechanisms of MAIs and only a few signaling pathways have been linked to 
MAIs (Figure 1.3). MAG has been shown to increase calcium levels in neurons 
and this is dependent on the presence of both p75 and NgR [107, 108]. MAG 
enhances calcium levels by activating protein kinase C (PKC) in a phospholipase 
C (PLC) dependent manner. Inhibitors of PKC function relieve growth inhibition 







growth factor receptor (EGFR) is transactivated in response to Nogo66 and 
MAG, and it is suggested that this is due to increases in calcium levels [111].  
 MAIs must signal to the cytoskeleton to cause growth cone collapse and 
inhibition of axon growth, and the Rho family of small GTPases is well 
characterized as modulators of the actin-myosin cytoskeleton. The Rho family of 
GTPases includes RhoA, Rac1, and Cdc42. The GTPases cycle between being 
in an active GTP-bound state and an inactive GDP-bound state, and nucleotide 
exchange is controlled by several distinct inactivating GTPase-activating proteins 
(GAPs), activating guanine nucleotide exchange factors (GEFs) and guanine 
nucleotide dissociation inhibitors (GDIs) that maintain GTPases in an inactive 
state[112]. RhoA activation has been implicated as an essential component of 
MAI downstream signaling; the involvement of Rac1 or Cdc42 is unknown. 
However, Rac1 activity has been linked to growth cone collapse downstream of 
ephrin-A2 and semaphorin 3A, suggesting it may promote growth inhibition 
through a MAI-independent pathway [113-115]. Inhibition of RhoA activity 
releases inhibition by MAG or myelin in cell culture and promotes regeneration of 
the optic nerve in mice [116-118]. It was also found that the receptor p75 upon 
MAG or Nogo stimulation associates with a RHO-GDI, releasing its inhibitory 
association with RhoA, and resulting in RhoA activation [65, 66]. Downstream of 
RhoA activation, Rho-associated kinase (ROCK) is an important relay point for 
signal transduction to the cytoskeleton. Our laboratory has discovered that Plenty 
of Src Homology 3s (POSH), a scaffold protein for the Rho GTPase, Rac, 
negatively regulates axon outgrowth. Additionally, POSH forms a signaling 
complex with the actin-myosin regulatory protein Shroom3 and its associated 
protein ROCK to negatively regulate axon outgrowth, potentially linking POSH to 
changes in cytoskeletal dynamics to regulate axon outgrowth[119]. 
  
1.9 Plenty of Src Homology 3s (POSH) 
 
Plenty of SH3s (POSH) is a multidomain scaffold protein compromised of 
four Src homology 3 (SH3) domains, a Rac binding domain (RBD), and a really 
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interesting new gene (RING) domain[120]. SH3 domains facilitate protein-protein 
interactions (PPIs) through proline rich regions (Figure 1.4). The presence of four 
SH3 domains highlights the role of POSH as a scaffold protein, as POSH could 
potentially associate with four distinct proteins through each SH3 domain. The 
RING domain classifies POSH as an ubiquitin E3 ligase. The E3 ubiquitin ligase 
family is large and structurally diverse, and specifies ubiquitin conjugation 
through their substrate recognition and the recruitment of a cognate E2 ubiquitin 
conjugating enzyme [121]. POSH levels are regulated by self-ubiquitination, 
however there remains minimal knowledge of additional substrates for 
ubiquitination by POSH.  
POSH was discovered through a yeast two hybrid screen for Rac 
interacting proteins that facilitate Rac-mediated activation of c-Jun N-terminal 
kinase (JNK)[120]. POSH is ubiquitously expressed with highest expression 
levels in the kidney, lung, and brain[120]. Through its RBD, POSH binds the 
GTP-loaded (active) form of Rac but not the GDP-loaded (inactive), facilitating 
the activation of a mitogen-activated protein kinase (MAPK) signaling pathway 
including: mixed-lineage kinase 1 (MLK1), mitogen-activated protein (MAP) 
kinase kinases (MKKs) 4 and 7, and JNK [120, 122]. POSH also associated with 
the mixed-lineage kinases, dual leucine zipper (DLK) and leucine zipper kinase 
(LZK) to facilitate JNK interaction. However, DLK and LZK do not contain a 
canonical CRIB (Cdc42/Rac interactive binding) motif, thus their activation of 
JNK may be Rac independent [123, 124]. POSH forms a multiprotein complex 
with the scaffold protein JIP (JNK interacting protein) to activate JNK and 
promote apoptosis, leading to the complex being termed PJAC (POSH-JIP 
apoptotic complex). In the PJAC, POSH binds members of the MLK family and 
GTP-Rac, while JIP associates with MKK4/7 and JNK (Figure 1.5A). The 
formation of the complex promotes JNK activation, and is stabilized by a feed-
forward loop enhancing JNK-mediated cellular events [125, 126]. The PJAC 
complex is regulated by Akt. Akt2 associates with POSH and phosphorylates 
MLK3, destabilizing the complex and causing it to disassemble[127]. Additionally, 









In the nervous system, the JNK pathway regulates neuronal cell death 
evoked by stress stimuli, such as: withdrawal of trophic support, DNA damage, 
and oxidative stress. Overexpression of POSH, MLKs, MKK4/7, or constitutively 
active JNK has been reported to be sufficient to cause cell death in neuronal and 
non-neuronal cells, however our laboratory has not observed this phenotype 
[120, 122, 129]. Neuronal apoptotic death induced by trophic support withdrawal 
can be reversed through the removal of POSH function by POSH siRNA and 
JNK activation by MLKs is enhanced by overexpression of POSH [122]. These 
results highlight the importance of the scaffold in mediating apoptosis through 
JNK activation. Additionally, ischaemic stress, the loss of blood supply to the 
brain, induces JNK pathway activation and this is followed closely by neuronal 
cell death [130].  Removal of POSH function results in decreased neuronal cell 
death after ischemia in rats, indicating that manipulation of POSH function is 
neuroprotective in this context. POSH’s role in apoptosis and neuronal cell death 
has also been characterized in Xenopus during early embryogenesis. Loss of 
POSH function resulted in neural tube defects that were similar to phenotypes 
seen with JNK deficient mice and MLK2 knockdown in Xenopus [131]. The above 
studies highlight a crucial role for POSH in JNK activation leading to apoptosis. 
However the POSH-JNK pathway and POSH itself have additional roles distinct 
from programmed cell death. 
 As a scaffold protein, POSH interacts with or regulates the function of 
many distinct proteins allowing POSH to affect diverse biological processes.  In 
Drosophila, the dorsal appendages on eggshells serves as a breathing tube for 
the developing embryo and provides a mechanism for air exchange if the embryo 
becomes submerged [132]. Ras signaling is important for synthesis of dorsal 
appendages and loss of Ras signaling results in eggs with a single dorsal 
appendage [133]. POSH was identified in a screen for enhanced loss of Ras 
phenotypes in the dorsal appendage, suggesting that POSH regulates cell shape 
changes during development [133]. On endosomes, POSH has been shown to 
regulate hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), 
which is involved in receptor down-regulation and multivesicular body biogenesis. 
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POSH targets Hrs for ubiquitination and subsequent degradation, potentially 
affecting normal cell morphology (Figure 1.5B) [134]. The E3 ligase function of 
POSH and its association with the endosome is also involved in the production of 
infectious HIV-1. POSH facilitates the sorting of HIV Gag viral polyprotein to the 
inner leaflet of the plasma membrane, where GAG induces virus-like particle 
budding and release [135]. Furthermore, the E3 ligase activity of POSH in the 
Drosophila immune system leads to degradation of the JNK activator, 
transforming-growth factor β (TGFβ)-activated kinase (TAK1), and subsequent 
termination of the immune response[136]. POSH has a role in calcium 
homeostasis through its association with the homocysteine-inducible ER protein, 
Herp. POSH-Herp binding increases the levels of Herp in the endoplasmic 
reticulum (ER), where Herp protects the cell after ER stress by controlling 
calcium homeostasis (Figure 1.5C) [137]. Lastly, our laboratory has reported a 
novel role for POSH as a negative regulator of axon outgrowth [119]. POSH 
assembles a signaling complex composed of Shroom3 and ROCK to inhibit axon 
length (Figure 1.5D). It was found that the RING domain is required for POSH-
mediated regulation of process outgrowth, suggesting a role for E3 ligase activity 
[119]. Through these collective studies, it is clear that POSH is able to regulate 
many diverse functions through the assembly of distinct protein complexes.  
   
1.10 Shroom3 
 
Shroom3, an f-actin and myosin binding protein, was first identified as a 
critical player in neural tube closure.  Shroom3 deficient mice exhibit neural tube 
closure defects where the neural folds fail to converge at the dorsal midline and 
“mushroom” outward [138]. Exencephaly, where the brain is located outside the 
skull, was observed in all homozygous mutant embryos. Additional neural tube 
defect phenotypes, such as craniofacial clefting and spina bifida were observed 
in a smaller percentage of the mutants, 87% (68/78) and 23% (21/93) 
respectively[138].  Shroom3 contains two highly conserved domains termed 
ASDs (Apx/Shroom domains). Proteins which contain an ASD domain have been 
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classified into the Shroom family and renamed: Shroom1 (APX), Shroom2 
(APXL), Shoom3, and Shroom4 (Kiaa1202) [139].  All four members of the 
Shroom family associate with cytoskeletal elements, and therefore are suggested 
to be involved in the control of cellular architecture. For example, Shroom1, 
Shroom2, and Shroom3 regulate the cellular distribution of γ-tubulin, linking the 
Shroom family to coordinating microtubule dynamics [140-142]. Shroom4 has 
also been shown to play a role in neural development and mutations have been 
linked to mental retardation[143].  
 Shroom3 is a key player in apical constriction, the process in which 
contraction of the apical side of a cell causes the cell to become wedge shaped. 
Apical constriction occurs during embryonic development where epithelial cells 
are undergoing morphological changes, including folding, invagination, and 
elongation. Correct formation of the neural tube requires these morphological 
changes to occur. Overexpression of Shroom3 in epithelial cells induces apical 
constriction as well as the recruitment of myosin II to the apical surface where it 
is hypothesized to elicit cell shape changes or maintain tension required for 
constriction [139, 144]. Both ASD domains of Shroom3 play a role in regulating 
actin-myosin dynamics to modulate cytoskeletal events. The ASD1 domain is 
involved in F-actin association, while the ASD2 domain recruits ROCK to 
regulate myosin II [145, 146]. The N-terminus of Shroom3 contains a post 
synaptic density 95/disclarge/zona occludens (PDZ) domain, providing an 
additional site for protein-protein interactions. 
 Shroom3 is widely expressed during embryonic development, suggesting 
roles in addition to apical constriction. Studies from our laboratory revealed that 
Shroom3 associates with POSH through the third SH3 domain of POSH [119]. 
The POSH binding region (PBD) of Shroom3 is located upstream of the ASD1 
and ASD2 domains, and downstream of the PDZ domain. Removal of Shroom3 
function by RNA interference (RNAi) in primary cortical neurons leads to 
enhanced axon length that is similar to the phenotype seen with POSH RNAi. 
The ASD1 and ASD2 domains are required for Shroom-mediated regulation of 
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axon length [119]. These results indicate a role for POSH, through Shroom3, as 




ROCK was first identified as an effector of the small GTPase Rho, 
facilitating Rho-induced formation of stress fibers and focal adhesions through 
the phosphorylation of myosin light chain (MLC) [147, 148].  There are two 
known isoforms, ROCKI and ROCKII, and both are ubiquitously expressed in 
rodents, although there is increased expression of ROCK II in muscle tissue and 
brain. ROCKs are serine/threonine kinases consisting of an amino-terminal 
kinase domain followed by a potential coiled-coil region, a Rho binding domain 
(RBD), and a C-terminal pleckstrin homology (PH) domain. ROCK is primarily 
located in the cytoplasm, however it can translocate to the cellular membrane 
when provided the proper stimuli [149].  
 The kinase activity of ROCKI and ROCKII is regulated in distinct 
mechanisms. The PH domain and the RBD function in the autoinhibition of 
enzymatic activity by interacting with the amino-terminal kinase domain [150]. 
Binding of activated GTP-bound Rho to the RBD is thought to open up the 
kinase, removing autoinhibition. ROCKII can also be activated in a Rho-
independent manner by association with arachidonic acid treatment in smooth 
muscle [151]. In vivo, ROCKI is truncated by caspase-3 in the c-terminus 
resulting in a constitutively active kinase [152, 153]. There is also evidence that 
ROCK can associate with additional small GTPases which can bind and 
selectively inhibit ROCK function. For example, the small GTPase, Gem, binds to 
ROCKII in a region adjacent to the Rho binding domain and expression of Gem 
inhibits ROCK from activating its downstream substrates [154]. This finding is 
interesting as it suggests that ROCK may have additional unknown roles 
downstream of other small GTPases independent of Rho. 
Following activation by Rho, ROCK regulates multiple signaling pathways 
that all have potential to modulate cytoskeletal functions downstream [149]. A 
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well studied target of ROCK phosphorylation is the light chain of myosin, also 
referred to as myosin light chain (MLC). Phosphorylation of MLC regulates 
myosin II function by promoting its interaction with actin, thereby activating 
myosin ATPase and enhancing cell contractility [155-157]. ROCK also 
phosphorylates myosin binding subunit (MBS) [157, 158]. MBS is one of three 
subunits of myosin light chain phosphatase (MLCP), a negative regulator of 
actomyosin contractility. Phosphorylation of MBS by ROCK causes MLCP to 
dissociate from myosin retaining myosin activity. Therefore, ROCK regulates 
contractility on multiple levels: activating contractility and inhibiting deactivation. 
Additionally, ROCK can regulate actin dynamics and microtubule stability through 
activation of LIM kinases and collapsing response mediator protein-2 (CRMP2), a 
neuronal protein that is involved in growth cone collapse [159, 160]. 
ROCK’s regulation of actin-myosin function is crucial to modulating axon 
outgrowth. Recently, ROCK function has been shown to mediate neuronal 
responses to myelin-associated inhibitory proteins (MAIs) [161]. The ROCK 
antagonist, Y-27632, can promote neurite growth on MAI substrates in vitro and 
enhanced regeneration in rats subjected to corticospinal tract transection. Four 
independent studies showed that Y-27632 treatment allows outgrowth on MAG, 
NogoA, and crude myelin in cerebellar granule neurons, cortical neurons, and 
dorsal root ganglion cells [58, 116, 118]. Y-27632 treatment in rodents subjected 
to corticospinal tract transection yielded enhanced sprouting of cortical spinal 
tract fibers and accelerated locomoter recovery, visualized by recovery of hind 
limb function [116, 118]. This was also observed in ROCKII knock-out mice [162]. 
Investigation into the molecular mechanism of ROCK signaling downstream of 
MAIs revealed that upon NogoA stimulation ROCK translocates to the cellular 
membrane and phosphorylation of myosin light chain is enhanced [161].  
However, further characterization of known ROCK effectors, such as LIMK and 
CRMP2, were not performed, therefore, the complete downstream signaling 
mechanism of MAIs through ROCK is unknown.  
The ASD2 domain of Shroom3 binds Rho associated kinase (ROCK) to 
localize ROCK to the epithelial apical junction where ROCK contributes to apical 
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constriction [145]. Our laboratory has shown that Shroom3 also recruits ROCK to 
the POSH complex where ROCK mediates axon outgrowth [119]. Interference 
with ROCK activity with the inhibitor Y-27632 or expression of a dominant 
negative domain of ROCK, which disrupts the Shroom3-ROCK interaction, leads 
to enhanced axon length. Our data suggests that ROCK is involved in the POSH 
pathway as a negative regulator of axon length. 
 
1.12 Mixed-lineage kinases: Dual leucine zipper kinase (DLK) and Leucine 
zipper kinase (LZK) 
 
The mixed-lineage kinases (MLKs) are a family of serine/threonine protein 
kinases that act in a mitogen-activated protein kinase (MAPK) signaling pathway. 
The name mixed-lineage comes from their kinase domain where the conserved 
subdomains contain homology with both serine/threonine and tyrosine kinases 
[163]. However, there is no evidence for MLKs having tyrosine kinase activity. 
There are three subfamilies of MLKs, classified on the basis of their domain 
arrangements and sequence similarities: the MLKs, the dual-leucine-zipper-
bearing kinase (DLK and LZK), and the zipper-sterile-α-motif kinases (ZAK). The 
MLKs (MLK1-4) are characterized by an amino-terminal src-homology-3 (SH3) 
domain, followed by a kinase domain, a leucine zipper region, and a Cdc42/Rac-
interactive binding (CRIB) motif, which promotes activation via Rac or Cdc42 
[164]. The MLK subgroup contains 75% sequence identity within their kinase 
domain and 65% identity from their SH3 domain to their CRIB motif. The c-
terminal ends are less homologous, potentially serving as regulatory sites for 
distinct cellular functions.  
DLK was identified using degenerative oligonucleotide-based PCR cloning 
in a screen to identify novel protein kinases[165]. LZK was isolated soon after 
from the human cerebellum[166]. DLK is an 888 amino acid protein, while LZK 
contains 966 amino acids. The proteins possess a kinase domain in their N-
terminus followed by two leucine zipper domains with 86.4% homology [165, 
166]. DLK and LZK lack the CRIB motif present in other MLK family members, 
and they are activated by dimerization rather than association of small GTPases. 
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DLK and LZK can form homo- and heterodimers, however there is evidence that 
only homodimers occur through the zipper domains, while heterodimers occur 
through additional binding regions in the N-terminus [124, 167]. DLK and LZK 
bind and phosphorylate MKK7 to activate JNK, and DLK has been shown to 
activate p38 through the phosphorylation of MKK4 [167, 168]. Additionally both 
proteins associate with the scaffold proteins POSH and JIP (JNK-interacting 
protein) to facilitate JNK activation [124, 169]. However, DLK is also held in an 
inactive, monomer state by JIP. Phosphorylation of JIP by JNK releases DLK and 
facilitates its dimerization, subsequent activation, and leads to further activation 
of JNK [170, 171]. This model suggests a feed forward mechanism of regulation 
for the DLK-JIP-JNK signaling pathway. Additionally, JIP tyrosine-
phosphorylation by Src family members increases the affinity of JIP for DLK, 
preventing the activation of JNK [172]. 
 In vitro, LZK is primarily known for inducing JNK activation and apoptosis, 
and its in vivo role is not well characterized. On the other hand, DLK has several 
roles defined in the nervous system. In Caenorhabditis elegans, a DLK homolog 
is required for axon regeneration by initiating the formation of new growth cones 
on severed axons through the activation of MKK4 and p38 [173].  In Drosophila 
melanogaster, DLK regulates synaptic growth through activation of JNK. 
Interestingly in both systems, DLK is negatively regulated by an E3 ubiquitin 
ligase protein family denoted PHR (human Pam, mouse Phr1, zebrafish Esrom, 
Drosophila Highwire, and C.elegans RPM-1)[174]. In a collection of studies using 
DLK knockout mice, researchers found that loss of DLK lead to defects in 
neuronal migration and axon outgrowth resulting in reduced size of the anterior 
commisure and corpus callosum[175]. Further studies revealed that DLK 
regulates axon outgrowth through JNK activation, followed by downstream 
activation of doublecortin (DCX) and microtubule-associated protein 1b (MAP1B) 
[175-177]. Collectively these studies highlight a role for DLK/LZK as regulators of 
axonal development and outgrowth upstream of JNK activation. 
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1.13 POSH is a negative regulator of axon outgrowth 
 
 Our laboratory identified a novel role for POSH as a negative regulator of 
axon length [119]. Removal of POSH function by RNA interference (RNAi) in 
differentiated P19 cells or primary cortical neurons from mice results in enhanced 
axon length.  The enhancement in axon length was not due to a increase in cell 
survival, which suggested that the signaling pathway mediating axon outgrowth is 
independent from its role in apoptosis[120, 122, 131, 178]. Consistent with this 
hypothesis, POSH binds the actin-myosin regulatory protein, Shroom3, through 
its third SH3 domain. RNAi-mediated interference of Shroom3 expression also 
results in long axons suggesting that POSH and Shroom3 work in concert to 
negatively regulate axon outgrowth.  
 Shroom3 regulates the actin-myosin cytoskeleton through its ASD1/2 
domains and we found that both domains are required for regulation of process 
length. Expression of the ASD1 domain in cortical neurons acts as a dominant 
negative to block the binding of endogenous Shroom3 to actin, and results in 
neurons with enhanced process length. Additionally, a Shroom3 mutant lacking 
the ASD2 domain is no longer able to regulate axon outgrowth. The ASD2 
domain regulates myosin II activity or localization through the recruitment of 
ROCK and interference with the ability of Shroom3 to bind ROCK results in 
enhanced process growth, indicating that interaction with ROCK is critical for 
Shroom3-POSH to regulate axon length [119, 144, 145]. Interestingly, loss of 
myosin IIA function reverses the POSH and Shroom3 long process phenotype, 
indicating that increased myosin II function may be the driving force in the 
POSH/Shroom3 phenotypes. As stated previously, ROCK regulates myosin II 
activity by phosphorylating myosin light chain and myosin light chain 
phosphatase[149]. However, it is unknown as to whether the POSH-Shroom3-
ROCK complex is directly regulating myosin II function or if enhanced myosin II 




 Collectively the research from our laboratory suggests that POSH 
assembles an axon growth inhibitory complex that links through Shroom3 and 
ROCK, directly or indirectly, to the actin-myosin network. However, the upstream 
signaling components relaying growth inhibition through the POSH complex 
remain unknown. Thus, this thesis aims to characterize the upstream molecular 
mechanism of axon growth inhibition mediated by the POSH complex. The 
elucidation of this signaling pathway will increase the knowledge of downstream 
inhibitory events and provide novel targets for therapeutic strategies to overcome 
neurite growth inhibition during development, and also in the adult CNS where 
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The regenerative and plastic capacity of the adult mammalian CNS is 
limited, contributing to poor functional recovery after injury or disease. CNS 
axons are capable of regenerating but fail to do so, in part because factors 
present in the CNS actively prevent axon outgrowth [1-4]. Factors that limit axon 
outgrowth and plasticity have been purified from CNS myelin and include myelin 
associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), 
and NogoA [1, 4-6]. In addition to limiting axon outgrowth and plasticity in the 
adult CNS, NogoA also regulates axon outgrowth and plasticity during 
development [6-13].  
Nogo66, an axon outgrowth inhibitory domain of NogoA, engages cell 
surface receptors, Nogo66 Receptor 1 (NgR1) and Paired Immunoglobulin-like 
Receptor B (PirB), to mediate intracellular signal transduction [7, 14-16]. NgR1 
links to Rho and its downstream effector Rho kinase to regulate cytoskeletal 
dynamics associated with growth cone collapse and inhibition of axon outgrowth 
[1, 4]. PirB is a recently identified receptor for myelin-derived inhibitory substrates 
[7, 11]. The signaling pathway activated when myelin derived inhibitors engage 
PirB is not known. However, in hematopoietic cells, where PirB signaling has 
been more extensively studied, phosphorylation of the receptor at specific 
tyrosines by src family kinases recruits SH2-homology-containing protein tyrosine 
phosphatases SHP1 and SHP2 [17, 18].  
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Plenty of SH3s (POSH, also known as SH3rf1) is an intracellular 
multidomain scaffold protein that regulates diverse biological functions, including 
apoptosis, calcium homeostasis, morphogenesis, and neuronal process 
outgrowth [19-25]. POSH contains multiple protein-protein interaction domains, 
including an amino-terminal RING domain, four Src homology 3 (SH3) domains, 
and a Rac binding domain. As a scaffold protein, POSH exerts its function 
through interacting partners, which include the actin-myosin regulatory protein 
Shroom3, the small GTPase Rac, and mixed lineage kinases [21, 22, 24, 26]. 
Our laboratory previously reported that POSH limits axon growth through a 
Shroom3-ROCK-myosin signaling pathway [22]. Here, we demonstrate that the 
scaffold protein POSH, in association with Shroom3 and the mixed lineage 
kinase LZK, relays axon outgrowth inhibition downstream of NogoA and PirB.  
 
2.2 Results 
2.2.1 POSH RNAi neurons are refractory to myelin and Nogo66-mediated 
inhibition of axon outgrowth 
 
In a previous report, we demonstrated that POSH limits axon outgrowth 
through a Shroom3-ROCK-myosin signaling pathway [22]. To determine whether 
myelin inhibitors signal to POSH to limit axon outgrowth, control neurons or 
neurons with RNAi mediated knockdown of POSH function were assessed for 
their ability to extend processes in the presence of CNS myelin.  Mouse primary 
embryonic cortical neurons were nucleofected with control or POSH RNAi 
expression vectors and cultured on poly-L-lysine/laminin (PLL) with or without 
purified myelin. The UI4-SIBR RNAi vectors express a single vector derived 
transcript for RNAi and GFP expression, with GFP expression identifying the 
transfected neurons [22, 27].  Process outgrowth in GFP-labeled cortical neurons 
was analyzed 72 hours after nucleofection and plating. Myelin reduced average 
process length of control RNAi transfected neurons to 66% of the length on PLL 
only (Figure 2.1A-B, G). POSH RNAi neurons exhibited increased process length 






 [22], indicating that POSH negatively regulates process outgrowth (Figure 2.1A, 
D, G). Strikingly, process length of POSH RNAi neurons was not reduced when 
plated on myelin (Figure 2.1D-E, G). The observation that POSH RNAi neurons 
are refractory to inhibition by myelin suggests that in primary cortical neurons 
myelin based inhibitors act through a signaling pathway that includes POSH.  
Several proteins in myelin limit process outgrowth, including NogoA [1, 5]. 
We tested whether Nogo66, a soluble domain of the NogoA ligand, inhibits 
process outgrowth of control or POSH RNAi neurons. Primary cortical neurons 
were nucleofected with control or POSH RNAi expression vectors and cultured 
on bacterially expressed and purified Nogo66. Process length was assessed in 
fixed, GFP-stained neurons. Nogo66 inhibited process length of control RNAi 
neurons (Figure 2.1A, C, G). In contrast, POSH RNAi neurons were refractory to 
the inhibitory action of Nogo66 (Figure 2.1D, F-G). This result suggests that 
Nogo66 signals to POSH to inhibit process outgrowth and that the inhibitory 
action of myelin is mediated, at least in part, through a NogoA/POSH signaling 
pathway.  
 
2.2.2 POSH associated proteins, Shroom3 and LZK, negatively regulate 
axon length and are intracellular signal transducers of myelin and 
Nogo66 
 
POSH regulates biological outcomes by assembling a protein interaction 
network, which includes the actin-myosin regulatory protein Shroom3 and the 
mixed lineage kinase LZK [24, 28]. To determine whether these known binding 
partners for POSH mediate myelin inhibition, primary cortical neurons were 
nucleofected with control, Shroom3, or LZK RNAi vectors and process outgrowth 
was analyzed in the presence or absence of myelin. Inhibition of Shroom3 
function by RNAi resulted in increased process length relative to control neurons 
when neurons were plated to PLL (Figure 2.1G), consistent with our previous 
study demonstrating that the POSH-Shroom3 complex inhibits process outgrowth 
[22]. Likewise, LZK RNAi cortical neurons exhibited increased process lengths 





consistent with a role for LZK as a negative regulator of process outgrowth. 
Plating to myelin did not inhibit process length of Shroom3 or LZK RNAi neurons 
(Figure 2.1G-H). In addition, process length was not decreased when Shroom3 
or LZK RNAi neurons were plated to Nogo66 (Figure 2.1G-H). Thus, reducing 
Shroom3 or LZK function with RNAi results in neurons that are refractory to 
myelin and Nogo66 inhibition. Taken together, the observations that POSH and 
its binding partners Shroom3 and LZK modulate responsiveness to myelin and 
Nogo66 identify the POSH complex as an intracellular signal transducer for 
myelin-derived inhibitors.  
 
2.2.3 POSH is required for Nogo66 inhibition of axon outgrowth in CGNs 
 
Since different neuronal cell types could utilize different mechanisms for 
Nogo66 inhibition and Nogo66 also inhibits axon outgrowth in cerebellar granule 
neurons (CGNs), we investigated whether POSH mediates inhibition of axon 
outgrowth in response to Nogo66 in postnatal CGNs [7, 29].  Like cortical 
neurons, POSH RNAi CGNs were refractory to the inhibitory action of Nogo66 
(Figure 2.3A-E), suggesting that a POSH-dependent mechanism operates in 
different neuronal cell types to inhibit axon outgrowth in response to Nogo66.  
 
2.2.4 Nogo inhibits axon outgrowth in both a cell-autonomous and non-
cell-autonomous fashion 
 
Like NogoA, POSH is expressed in mouse embryonic cortical neurons in 
vitro (Figure 2.4A) [10, 30, 31]. Given this overlap in expression, RNAi mediated 
reduction of NogoA function was used to investigate the potential for signaling 
from endogenous NogoA to POSH. Cortical primary neurons were nucleofected 
with control or Nogo specific RNAi expression vectors to determine if Nogo 
expression in cortical neurons limits axon outgrowth. The Nogo gene encodes for 
three variants, NogoA-C that share a carboxyl terminal neurite outgrowth 
inhibitory domain, Nogo66 [1,[14, 15]. In addition, NogoA has a unique domain, 









construct targets the exon unique to NogoA, which is absent from NogoB and 
NogoC, and thus this construct specifically targets NogoA (Figure 2.5). Process 
length in Nogo-3 RNAi-depleted neurons was increased relative to control 
(Figure 2.6A), as expected if NogoA limits process outgrowth. Similar results 
were obtained with a second siRNA, Nogo-1, that targets the 3’UTR of the Nogo 
mRNA, reducing the expression of Nogo isoforms, NogoA/B (Figure 2.5). The 
Nogo-1 RNAi construct is also expected to reduce the expression of NogoC 
since the 3’UTR is conserved among the mRNAs for the three Nogo isoforms 
and RT-PCR analysis indicates that NogoC, along with NogoA/B, is expressed in 
cortical neurons (Figure 2.4B). Together, these results support a role for NogoA 
as an inhibitor of process outgrowth of cortical neurons grown in culture, and 
suggest that NogoB and C do not function redundantly with NogoA to regulate 
process outgrowth.  
Since RNAi mediated reduction of NogoA function in neurons enhances 
process length, this result suggests that NogoA acts in a cell autonomous, 
intrinsic fashion to inhibit process outgrowth.  In addition, NogoA can act in a 
non-cell autonomous fashion, as process outgrowth of control cortical neurons is 
inhibited when plated directly onto purified Nogo66 protein (Figure 2.1 and Figure 
2.6B). Finally, purified Nogo66 protein, added externally, reverses the NogoA 
RNAi phenotype (Figure 2.6B), unlike the addition of Nogo66 to PirB RNAi 
neurons (compare Figures 2.6B and Figure 2.1H), indicating that cells in which 
NogoA is reduced can still respond to external Nogo66 as expected. 
 
2.2.5 Suppression of Myosin IIA function reverses the Nogo RNAi 
phenotype 
 
Myosin IIA RNAi reverses the increase in process length associated with 
RNAi-depletion of POSH or the POSH associated proteins, Shroom3 and LZK 
(Figure 2.7A and [22]). However, myosin IIA RNAi does not reverse the increase 
in process length resulting from RNAi-mediated reduction of the neurite 












which a reduction in myosin IIA function suppresses axon outgrowth in neurons 
deficient in POSH function, but not Ephrin B2 or Robo1, remains to be 
determined.  Nonetheless, these observations suggest that myosin IIA reduction 
of function can distinguish among pathways that negatively regulate axon 
outgrowth, with some pathways sensitive to myosin IIA reduction of function (e.g. 
POSH) and others insensitive (Ephrin B2, Robo), and this provides a useful tool 
to assess whether specific components might be associated with a POSH 
signaling pathway for axon outgrowth inhibition.   
The ability of myosin IIA RNAi to suppress axon outgrowth was used to 
test whether NogoA signals to POSH to regulate process outgrowth. Primary 
cortical neurons were nucleofected with control, POSH or Nogo RNAi expression 
vectors, together with a myosin IIA RNAi expression vector. As reported 
previously, control neuron process length was unaffected by myosin IIA RNAi, 
and POSH RNAi neuron process length was reduced by myosin IIA RNAi (Figure 
2.7B). Process length of Nogo RNAi neurons was also reduced by myosin IIA 
RNAi (Figure 2.7B), consistent with the hypothesis that NogoA signals through a 
POSH dependent pathway to regulate process outgrowth.  
 
2.2.6 LZK is a downstream effector of a Nogo/POSH signaling pathway 
 
Next, suppression analysis was used to test the hypothesis that LZK is a 
functional effector for Nogo signaling and to order the genes in the signaling 
pathway. If increased expression of LZK can compensate for loss of Nogo 
function, then this observation would support a role for LZK as a downstream 
effector of Nogo signaling. Cortical neurons were nucleofected with a Nogo RNAi 
expression vector and a control vector or a vector that expresses catalytically 
active or inactive forms of LZK. The efficiency of nucleofection of both plasmids 
was 94% (data not shown). Ectopic expression of wild type, but not catalytically 
inactive, LZK suppressed the enhanced process length phenotype exhibited by 






RNAi knockdown phenotype by increased expression of LZK is consistent with 
a model in which Nogo/POSH signaling is mediated, at least in part, by LZK. It is 
also possible that increased LZK activity suppresses by activating a 
compensatory signaling pathway, not directly linked to NogoA function. However, 
this is unlikely because increased expression of LZK did not suppress process 
outgrowth of POSH RNAi neurons (Figure 2.8F), indicating that LZK suppression 
of process outgrowth requires the POSH scaffold. Together, these observations 
indicate that LZK regulates process outgrowth inhibition in a POSH-dependent 
manner downstream of NogoA.  
 
2.2.7 The PirB receptor transmits inhibitory signal from myelin and 
Nogo66 to the LZK-POSH complex 
 
PirB is a functional receptor for Nogo and MAG in CGNs and dorsal root 
ganglion neurons [7]. If PirB transmits axon outgrowth inhibitory signals in cortical 
neurons, then reducing PirB function with RNAi should lead to increased process 
length. Cortical neurons with an RNAi mediated reduction in PirB function 
exhibited an increase in process length (Figure 2.9A), consistent with PirB 
functioning as a negative regulator of process outgrowth. A second RNAi 
construct, targeting a different PirB sequence, gave a similar result (data not 
shown and Figure 2.9B). Further, if PirB is acting as a receptor to transmit 
inhibitory signals from myelin and NogoA in cortical neurons, then PirB RNAi 
neurons should be refractory to myelin and Nogo66 inhibition. Process length of 
PirB RNAi neurons was unaffected by myelin and Nogo66 (Figure 2.1H), 
supporting a role for PirB in myelin/Nogo mediated inhibition in cortical neurons. 
Moreover, if PirB acts through POSH to inhibit process outgrowth, then myosin 
IIA RNAi is expected to reverse the PirB RNAi phenotype. Indeed, PirB RNAi 
neuronal process length was decreased by RNAi mediated reduction in myosin 
IIA (Figure 2.9C). Finally, if PirB signals to the POSH complex, then ectopic 
expression of LZK is expected to reverse the PirB RNAi phenotype. 
Overexpression of LZK in PirB RNAi-depleted cortical neurons reduced process 











Together, these results define a central role for the POSH complex in 
relaying process outgrowth inhibition downstream of NogoA and PirB (Figure 
2.10). Supporting a role for POSH as a downstream effector of myelin-based 
inhibitory signals, RNAi-mediated reduction in POSH function results in primary 
cortical neurons that robustly extend processes in the presence of CNS myelin, 
in contrast to control neurons, which are inhibited by myelin. As a scaffold 
protein, POSH operates through co-associating binding partners. POSH interacts 
with the actin-myosin regulatory protein Shroom3 to regulate process outgrowth 
inhibition  and we demonstrate here that neurons with RNAi-knockdown of 
Shroom3 function are refractory to the inhibitory action of CNS myelin, supporting 
a role for the POSH/Shroom3 complex in process outgrowth inhibition 
downstream of myelin [22]. Neurons with an RNAi-mediated reduction in a 
second POSH interacting protein, the mixed lineage kinase LZK, are also 
refractory to the inhibitory action of myelin, providing further support for a key role 
for the POSH complex in transmitting axon outgrowth inhibitory cues from CNS 
myelin-derived inhibitors.  
PirB is a receptor for Nogo66, and our observations are consistent with 
PirB signaling to POSH to mediate process outgrowth inhibition in cortical 
neurons [7, 32]. First, RNAi-mediated reduction of PirB in primary cortical 
neurons results in increased neuronal process length and prevents inhibition by 
myelin or Nogo66, indicating that PirB, like POSH RNAi, negatively regulates 
process length in cortical neurons. Second, overexpression of the POSH-
associated effector protein LZK suppresses the PirB RNAi-mediated increase in 






Nogo RNAi neurons. However, increased expression of LZK does not suppress 
the POSH RNAi enhanced process outgrowth phenotype, arguing that LZK does 
not suppress by simply activating a compensatory signaling pathway unlinked to 
PirB and POSH, but instead requires the POSH scaffold.  
Finally, inhibition of myosin IIA function reverses the PirB phenotype, as 
well as the Nogo RNAi-mediated enhancement of process outgrowth. MyosinIIA 
RNAi reverses the increase in process length under some conditions but not 
others [22]. The mechanism by which loss of myosin IIA function is able to 
shorten process length under some conditions but not others remains to be 
determined. Nonetheless, that reduction of both ligand and receptor (Nogo/PirB) 
can be reversed by reduction of myosin IIA function, matching what is observed 
for POSH and POSH-associated proteins, further supports the proposed pathway 
of NogoA-PirB-POSH. Collectively, these observations implicate the PirB 
receptor as a critical component in signaling process outgrowth inhibition reliant 
on POSH function. In hematopoietic cells, PirB signals by recruitment of the 
tyrosine phosphatases SHP1/2 [17, 18]. Likewise, in neurons responding to 
myelin inhibition, PirB may recruit SHP2 to signal to POSH, but the identity of 
potential SHP2 substrate(s) in this pathway remains to be determined. 
Further, these studies suggest that neuronally expressed NogoA limits 
axon outgrowth in a cell autonomous, intrinsic fashion, as RNAi-mediated 
reduction in cortical neurons enhances axon outgrowth. In contrast to neurons in 
which PirB or POSH/Shroom3/LZK are inhibited by RNAi, external application of 
Nogo66 to Nogo RNAi knockdown neurons inhibits enhanced process outgrowth. 
This is consistent with the model that the NogoA RNAi phenotype represents a 
loss of an autocrine signal for PirB, whereas disruption of PirB or POSH complex 
function prevents inhibition by either extrinsic or autocrine NogoA. The existence 
of autocrine Nogo inhibition also suggests an explanation for increased process 
outgrowth from POSH RNAi neurons in the absence of external inhibitory 
molecules [22]. Intriguingly, multiple inhibitory domains reside within Nogo, yet 
Nogo66 alone is sufficient to suppress the Nogo RNAi phenotype, highlighting 
the important role of this domain in mediating process outgrowth inhibition. The 
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ability of NogoA to limit process outgrowth in cis may function to limit axon 
outgrowth and plasticity during development [6-13]. Collectively, these results 
indicate that extrinsic and intrinsic mechanisms for impeding axon outgrowth 
converge on the POSH scaffold complex. Whether POSH signaling is 
downstream of CNS axon outgrowth inhibitors, in addition to NogoA/Nogo66, is 
an important question to be addressed in future studies. 
Several Nogo isoforms are expressed in neurons, NogoA-C. All three 
isoforms contain the Nogo66 C-terminal inhibitory domain and are reported to 
localize to the plasma membrane [33]. Surprisingly, RNAi-mediated reduction of 
NogoA function alone is indistinguishable from RNAi-mediated reduction of all 
three Nogo isoforms simultaneously, indicating that NogoB and C fail to 
compensate for NogoA deficiency. Perhaps unique sequences present in NogoA 
enable the protein to fold in a conformation that facilitates binding to a Nogo 
receptor residing in the same membrane (in cis).  
Proteins present in CNS myelin, including NogoA, are a major impediment 
to the repair of the injured CNS. The results presented here demonstrate a novel 
function for the POSH scaffold in signaling process outgrowth inhibition in 
response to NogoA, and delineate a new signaling pathway for process 
outgrowth inhibition, comprised of NogoA, PirB, POSH and LZK. 
Identification of intracellular signaling components mediating myelin 
inhibition provides potential new targets for the development of therapeutics 
aimed at restoring function in the injured CNS. Blockade of POSH scaffold 
function, or the function of POSH associated proteins, has the potential to 
enhance axon outgrowth and plasticity, and functional recovery in the injured 
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2.5 Materials and Methods 
2.5.1 Antibodies 
 
For axon outgrowth assays, cells were stained with anti-green fluorescent 
protein (GFP) rabbit primary antibody (Invitrogen) and Alexa Fluor 488 goat anti-
rabbit secondary antibody (Molecular Probes). For western blots the following 
primary antibodies were used: goat anti-Nogo (N18) (Santa Cruz), anti-ILT-5/PirB 
(C-19) (Santa Cruz), rabbit anti-Actin (Sigma), and rabbit anti-GFP (Invitrogen). 
Secondary antibodies used were: Goat Anti-Rabbit IgG Horseradish Peroxidase  
(HRP) Conjugate (BioRad) and Bovine anti-goat IgG HRP (Santa Cruz).  
 
2.5.2 Expression constructs and RNAi 
 
pUI4-SIBR-GFP is a short interfering RNA (siRNA) expression vector that 
co-expresses the GFP protein and a siRNA from an intronic expression cassette 
(the SIBR cassette) based on the miR-155 microRNA precursor [22, 27]. For 
each siRNA, a pUI4-SIBR-GFP vector expressing one to four identical tandem 
copies of the siRNA SIBR cassette was constructed [22, 27]. POSH-6, luciferase 
(a functional control RNAi vector), Shroom3-3, and myosinIIA-1 are described in 
[22]. The sequences of LZK, Nogo and PirB siRNAs are: LZK-1, 5' 
UUCAUCGGGACUGUUCGAGUGG 3'; LZK-2, 5' 
AUCAAUGUUACAGUAGCCGGAG 3'; Nogo-1, 5' 
AAUCUUUGAAAUGACGGUUACG 3'; Nogo-3, 5' 
UAUACCGUCAUAACUAACUGGA 3'; PirB-294, 5' 
AACAAUAACAGCGAUAUUGCCC 3'; and, PirB-874 siRNA 5' 
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AACAUCGAUAUUGACCUGCAUU 3'. Western blot analysis confirmed knock-
down of endogenous NogoA and PirB (Fig. S4). To construct CS2+NFLAG LZK, 
an N-terminally FLAG tagged construct, LZK was cloned by RT-PCR from RNA 
isolated from adult mouse brain. Kinase dead LZK was constructed by site-
directed mutagenesis, AAG being converted to GCG, substituting lysine 195 to 
alanine. ATP fails to bind at the active site in the mutant protein, resulting in a 
catalytically defective kinase-dead mutant [28]. 
 
2.5.3 Preparation of myelin and recombinant proteins 
 
Myelin extracts were prepared from adult rat brains, as described [34]. 
His-SUMO-conjugated Nogo66 (amino acids 1055-1079) or His-SUMO was 
expressed overnight at 25°C in Escherichia coli purified on Ni-NTA His Bind 
Resin (Qiagen). Briefly, E.coli were lysed by sonication in PBS+ (PBS, 0.1mM 
PMSF, 0.35mg aprotinin, 0.1% -mercaptoethanol, 10mM imidazole, 2nM 
leupeptin). Triton X-100 was added to the lysate at 1% of the final volume. 
Lysates were incubated with Ni-NTA His Bind Resin for 1 hour at 4°C and 
washed three times in PBS+ with 300mM NaCl. Protein was eluted from the 
beads with elution buffer (50mM NaHPO4, 300mM NaCl, 250mM imidazole) and 
25% glycerol was added. Protein concentration was determined by Bradford 
assay (BioRad) and Coomassie gel with Bovine serum albumin (BSA) standards. 
 
2.5.4 Axon outgrowth Assays 
 
4-well chamber slides (Fisher Lab Tek II) were coated for 4 hours with 10 
µg/ml poly-L-lysine then overnight with 2µg/ml laminin (Invitrogen) or overnight at 
4°C with laminin+myelin, laminin+control His-SUMO (2.5µg /cm2), or laminin+His-
SUMO Nogo66 (2.5µg /cm2).  After overnight incubation, unbound substrates 
were removed by rinsing with PBS. Cortical primary progenitors were cultured as 
previously described [22].  Primary progenitors were nucleofected with a total of 
6µg of DNA: 4.5µg of pUI4 vector and 1.5µg of empty vector control, pCS2-
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NFLAG LZK, or pCS2-NFLAG LZK KD.  In Fig. 2B, 4B, and S2B, cells were 
nucleofected with 6µg of DNA: 3µg of pUI4 vector and 3µg of pUI4-myosin IIA 
RNAi expression vector. Cells were fixed in 3.7% formaldehyde 72 hours post-
nucleofection. Cells were stained with an anti-GFP primary antibody (Invitrogen) 
and Alexa Fluor 488 goat anti-rabbit secondary antibody (Molecular Probes). The 
efficiency of co-nucleofection of two different plasmids in primary cortical neurons 
is 94%.  Co-nucleofection efficiency was determined by nucleofecting two 
plasmids expressing different markers (mCherry or GFP) and the percentage of 
cells expressing GFP, mCherry or both markers was determined in two 
independent experiments.  
 
2.5.5 Measurement of Process Length 
 
The length of the longest process per cell was measured in photographs 
of fixed, GFP stained neurons with the polyline function in MicroSuite imaging 
software version 5.0 (Olympus, Tokyo, Japan) [22]. For Fig. 2A-B, 3E-F, 4A-B, 
and S2, processes 50µm (3 times the length of the cell body) or greater were 
measured. In Fig. 1, 2C, and S1, using the box function in the MicroSuite imaging 
software, the longest process per cell for all the cells within the box was 
measured. Results are presented as average process length, determined from 
three independent nucleofections, with a total of 325-810 GFP-positive neurons 
measured per condition, except for Fig. 3E where the total number of neurons 
measured from the three independent nucleofections was 237-312.  Statistical 
significance was assessed using the Students t-test. The data sets analyzed in 
the t-test were the measurements of the total number of GFP-positive neurons 
from three independent nucleofections. 
 
2.5.6 Cerebellular Granule Neurons 
 
Cerebellular Granule neurons (CGNs) were isolated from the cerebellum 
of post-natal day (P) 8 mice as described [35]. CGNs were nucleofected as 
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described [36, 37] with a total of 4µg of DNA: luciferase (control RNAi vector) or 
POSH-6 RNAi vector. Cells were plated onto 4-well chamber slides incubated for 
4 hours with 10 µg/ml poly-L-lysine then overnight with 2µg/ml laminin or 
laminin+myelin at room temperature, laminin+control His-SUMO (2.5µg /cm2) or 
laminin+His-SUMO Nogo66 (2.5µg /cm2) at 4°C. 24 hours post-nucleofection 
cells were fixed with 3.7% formaldehyde. Cells were incubated with rabbit anti-
GFP primary antibody  (Invitrogen) and neuronal class III -tubulin monoclonal 
antibody TuJ1 (Covance), followed by detection with Alexa Fluor 488 goat anti-
rabbit (Molecular Probes) and Alexa Fluor 594 goat anti-mouse secondary 
antibodies (Molecular Probes). Average process length was quantified as 
described above and in [22]. 
 
2.5.7 Reverse Transcription-PCR 
 
RNA was purified from untransfected cortical neuron cultures (RNeasy 
kits, QIAGEN) and genomic DNA was removed from RNA samples using RNase-
Free DNase (QIAGEN), as recommended. Reverse transcription (RT) was 
performed using SuperScript II (Invitrogen) and Random Primer 12 (NEB) at 
25°C for 10 min, 42°C for 1 hr, and 72°C for 15 min. cDNA samples were 
analyzed by PCR (Expand High Fidelity PCR system; Roche) with the following 
primers: POSH F1, 5’ CAGGTCCATATAAGCACCACTG 3’; POSH R1, 5’ 
GGTAGGGGACATCTGAAGGGA 3’; POSH F2, 5’ 
GTGACTAAAGAGCACAAAGCAG 3’; POSH R2, 5’ 
CAAGGCACACTTTACACATCAG 3’; Nogo F1, 5’ GTGCCCTTATTGCTTCCAAA 
3’; Nogo R3, 5’ TCTGGATAGCTTGGATCACACCCTTA 3’; Nogo F3 5’ 
CAGGGGCTCGGGCTCAGT 3’; Nogo F-C 5’ 
ATGGACGATCAGAAGAAACGTTGGAA 3’; HPRT forward, 5’ 
CAAACTTTGCTTTCCCTGGT 3’; HPRT reverse, 5” 
CAAGGGCATATCCAACAACA 3’. Nogo F1, Nogo F3 and Nogo R3 have been 
previously described [38].  PCR products were analyzed by agarose gel 
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electrophoresis. Similar results were obtained with two independent RNA 
samples.  
 
2.5.8 Western Blot Analysis to test efficacy of RNAi constructs 
 
Western blot analysis was performed to test the ability of the siRNAs to 
target endogenous Nogo. Cellular extracts were prepared from transiently 
transfected, puromycin selected P19 cells, as previously described [22, 39]. To 
test the efficacy of the vector expressed PirB siRNAs, HEK 293 cells were 
transfected with a PirB expression construct together with a control or PirB RNAi 
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Chapter 3  
The Shp2 phosphatase suppresses axon outgrowth by regulating the 




Traumatic injury or disease to the adult central nervous system (CNS) often 
results in severed neuronal axons, leading to cell death and a loss of neuronal 
signaling and connectivity. Deficits in functional connectivity between neurons 
can lead to severe physical and mental impairments. Recovery after these 
injuries is rare, due to the limited capacity of the CNS to regenerate damaged 
neurons and their axons [1, 2]. Myelin-associated inhibitors (MAIs) of axonal 
growth and regeneration play a crucial role in the inability of the adult central 
nervous system to recover after injury or disease. The three major MAIs are: 
MAG, NogoA, and OMgp [1-3]. Blocking the action of these proteins and/or their 
receptors leads to enhanced regeneration of axons after injury, suggesting that 
circumventing the action of these inhibitors could be a strategy to enhance axon 
outgrowth of injured neurons [3, 4]. Complicating therapeutic strategies is the 
presence of multiple receptors for the inhibitory proteins including the Nogo-66 
receptor (NgR1) and paired immunoglobulin-like receptor B (PirB). Additionally, 
NgR1 and PirB receptors bind all three MAIs [3, 5-7]. The complexity at the 
neuronal cell surface suggests that blocking the intracellular signaling pathways 
regulated by MAIs may be a complementary and perhaps more efficacious 
strategy to enhance axon growth after injury.  
Previous studies in our laboratory have revealed a novel role for the 
intracellular scaffold protein POSH as a regulator of axon outgrowth in neurons 
[8, 9]. POSH mediates this function by facilitating the assembly of a signaling 
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module composed of the actin myosin regulatory protein Shroom3, Rho-
associated kinase (ROCK), and leucine zipper kinase (LZK) [8, 9]. Loss of 
function of any member of the complex or inhibition of complex assembly leads 
to an enhancement of axon length, indicating the POSH module negatively 
regulates axon length [8]. Through the receptor PirB, the POSH complex relays 
inhibitory signals from NogoA, specifically a 66-amino acid loop of NogoA termed 
Nogo66 [8]. These studies delineated a novel intracellular signaling pathway for 
process growth inhibition by Nogo66, comprised of NogoA, PirB, POSH, LZK, 
Shroom3, and ROCK. However, the molecular mechanism by which growth 
inhibitory signals are relayed from the receptor PirB to the POSH complex is 
unknown.  
Shp2 is an ubiquitously expressed, mammalian, non-transmembrane, 
protein tyrosine phosphatase. Shp2 contains two N-terminally located src-
homology 2 (N-SH2 and C-SH2) domains, a central phosphotyrosine 
phosphatase domain (PTP), a C-terminal tail with tyrosyl phosphorylation sites, 
and a proline-rich motif [10]. In the absence of a tyrosine-phosphorylated binding 
partner, the N-terminal SH2 domain binds the phosphatase domain blocking its 
active site [11, 12]. Shp2 is involved in many signaling pathways including 
Ras/ERK MAP kinase pathway and the JAK/Stat pathway [10, 13]. In 
macrophages, immunoprecipitation experiments using Shp1 (a Shp2 family 
member) discovered a 130-kDa phosphotyrosyl protein that was constitutively 
associated with Shp1 through its SH2 domains [14]. In further experiments, the 
identity of the 130-kDa protein was determined to be PirB and it was shown that 
Shp2 associates with PirB in a similar mechanism as Shp1 [15]. The cytoplasmic 
domain of PirB contains three potential immunoreceptor tyrosine based inhibitory 
motifs (ITIM), I/V-X-pY-X-X-L/V/I which are known binding sites for Shp1, Shp2, 
and SH2 domain-containing inositol phosphatase (SHIP)  [16-18]. PirB‟s third 
and fourth ITIMs are important for recruitment of Shp2 and downstream 
signaling[19]. In immune cells, PirB has been classified as an inhibitory receptor; 
the recruitment and activation of Shp1/2 leads to disruption of signaling cascades 
initiated by the activating receptor PirA [20, 21].  
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In neurons, PirB and Shp2 associate and the interaction is dependent on 
the intracellular domain [22]. PirB is a receptor for myelin-derived inhibitory 
substrates and studies using a truncated mutant of PirB have shown that the 
intracellular domain is important for relaying myelin inhibitory cues [22]. 
Additionally, a transgenic mouse for the truncated form of PirB displays 
increased ocular-dominance plasticity suggesting that PirB acts as a negative 
regulator of neuronal stability/plasticity [5, 22]. Recent studies have also shown 
that PirB and Shp2 together with p75, a co-receptor for NgR1, negatively 
regulate TrkB signaling to modulate axon outgrowth [23, 24]. Together these 
studies highlight the role of PirB and Shp2 as regulators of signaling both in the 
nervous system and in the immune system.   
 In this study, we report that Shp2 relays Nogo66-growth inhibitory signals 
downstream from the receptor PirB and its activity as a phosphatase is required 
for this function. Nogo66 stimulation induces an enhancement in the association 
of tyrosine-phosphorylated proteins with Shp2. LZK is tyrosine phosphorylated 
and binds to a Shp2 substrate trap mutant, suggesting that LZK is a Shp2 
substrate and its function is regulated by phosphorylation events. Interestingly, a 
close family member of LZK, DLK, is also a negative regulator of axon length and 
an intracellular signaling protein for Nogo66, suggesting functional redundancy of 
the kinases. However, DLK cannot compensate for the loss of PirB in CGNs and 
is not trapped by Shp2, suggesting that DLK and LZK undergo selective 
regulation. Finally, the POSH complex also relays inhibitory signals from MAG, 
indicating that the POSH complex may be a convergence point for MAIs. 








3.2.1 The Shp2 phosphatase is required for NogoA-mediated growth 
inhibition 
 
In neurons and in immune cells, PirB and Shp2 associate and the 
interaction is required for downstream signaling of the myelin-inhibitory protein 
MAG [20-23]. PirB is a functional receptor for NogoA in cerebellar granule 
neurons (CGNs) as reducing PirB function by RNA interference (RNAi) leads to 
increased process length and the neurons are refractory to Nogo66 inhibition 
(Figure 3.1). To determine if PirB is facilitating Nogo66 growth inhibition through 
Shp2, the ability of Shp2 to compensate for the loss of PirB function was tested. 
Specifically, we tested whether overexpression of Shp2 would suppress the PirB 
long axon phenotype or restore growth inhibition to PirB RNAi neurons on 
Nogo66. To perform these suppression analysis experiments, constitutively 
active or catalytically inactive Shp2 was expressed in PirB RNAi CGNs. In the 
absence of a receptor or activating protein, Shp2 is held in an inactive, folded-
conformation through the interaction of its N-terminal SH2 domain with the 
protein tyrosine phosphatase domain [12, 25].  Interaction of Shp2 with specific 
phosphorylated residues on activating proteins relieves this auto-inhibition [10, 
11]. To mimic activation, a glutamate 76 to lysine mutation was made which 
disrupts the ability of the SH2 domain from interacting with its tail, resulting in a 
constitutively active or receptor independent Shp2 mutant [10-12]. Ectopic 
expression of Shp2 E76K in PirB RNAi neurons reduced process length to 
control levels and was able to restore growth inhibition on Nogo66 (Figure 3.1). 
These results indicate that Shp2 function is downstream of PirB and is involved 
in mediating inhibitory signals from Nogo66. 
 To extend this analysis, a phosphatase dead Shp2 mutant was 
constructed by mutating arginine 465 to methionine (RM). This invariant arginine 
is located in the active site of the phosphatase where it coordinates and 
stabilizes the phosphate group on the substrate [11, 12, 25].  The RM mutant 
was constructed in the E76K background to create a double mutant that resides 






Shp2 RM/E76K was not able to complement the loss of PirB by RNAi or restore 
Nogo66 growth-inhibition (Figure 3.1). Collectively, these results show that Shp2 
is downstream of NogoA/PirB signaling and the phosphatase activity of Shp2 is 
necessary for mediation of NogoA/PirB growth inhibition in CGNs.  
 
3.2.2 Regulation of axon outgrowth by Shp2 is dependent on the POSH 
complex 
 
The assembly of the POSH complex, consisting of POSH, LZK, and 
Shroom3, is crucial for the regulation of axon outgrowth and NogoA mediated 
growth inhibition [8, 9]. To determine whether Shp2 relays growth inhibitory 
signals through the POSH module, the ability of Shp2 to compensate for the loss 
of POSH or LZK was tested. The loss of POSH or LZK function in CGNs by RNAi 
results in a long process phenotype (Figure 3.1 and [8, 9]). Overexpression of 
Shp2 E76K is not able to complement the loss of POSH or LZK function (Figure 
3.1). Also, Nogo66-mediated growth inhibition is not restored by ectopic 
expression of activated Shp2, indicating Shp2 requires the presence of POSH 
and LZK to mediate inhibitory signals and is not functioning through a separate 
inhibitory pathway. Importantly, these results show that Shp2 signaling occurs 
upstream of or in concert with the POSH/LZK signaling module.  
 
3.2.3 Nogo66 enhances Shp2 association with tyrosine-phosphorylated 
proteins 
 
Since the phosphatase activity of Shp2 and the presence of the POSH 
complex members are required for Shp2 to relay NogoA mediated growth 
inhibition, we hypothesized that Shp2 is acting on a member of the POSH 
complex. A widely used method for identifying physiological substrates of protein 
tyrosine phosphatases (PTPs) is to create a “substrate trap” by mutating specific 
amino acids in the catalytic domain of PTPs [15, 26, 27]. The trapping mutants 
are able to bind substrates but cannot dephosphorylate them.  Shp2 contains a 
conserved catalytic domain, which contains twenty-seven invariant residues, and 
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mutation of D425A and C459S has been reported as an effective substrate trap 
[15, 26, 27]. The cysteine residue acts as a nucleophile on the phosphorus atom 
of the substrate, followed by cleavage of the scissile P-O bond, which is 
facilitated by the aspartate [11, 12, 25]. The suppression of P-O cleavage is 
thought to stabilize and enhance the phosphatase-substrate interaction. To 
identify substrates of Shp2 downstream of NogoA, the DA/CS mutation was 
generated in the isolated PTP domain of Shp2, as well as in full-length Shp2.  
Using the substrate trap method, Nogo66 dependent increases or 
decreases in tyrosine phosphorylated proteins were assessed. CGNs were 
stimulated with Nogo66 for 15 minutes followed by pull-down analysis with Shp2 
Wild-type (WT) and DA/CS PTP domains purified from E.coli as GST fusion 
proteins. Western blot analysis was performed to examine levels of tyrosine 
phosphorylated proteins (Figure 3.2A). In the native assay, no interacting 
proteins were trapped or detected with or without Nogo66 treatment. To increase 
the pool of phosphorylated proteins in the cells and to enhance the sensitivity of 
the assay, CGNs were pretreated with the phosphatase inhibitor pervanadate 
and trapped Shp2 substrates were detected (Figure 3.2A).  Shp2 PTP DA/CS 
trapped at least eight tyrosine-phosphorylated proteins of differing molecular 
weights. No phosphorylated proteins were detected using WT PTP, indicating 
that the substrate trap was functioning as expected. Upon Nogo66 treatment, 
there is enhanced trapping of the tyrosine-phosphorylated proteins, suggesting 
potential Shp2 substrates. Three bands which correspond with the molecular 
weights of 200kDa, 120kDa, and 80kDa could be Shroom3 (198kDa), LZK 
(100kDa), and/or POSH (89kDa). Endogenous POSH, Shroom3, or LZK were 
not detected using protein specific antibodies in either the pull downs or in 
cellular extracts, the latter suggesting endogenous protein levels may be below 










3.2.4 LZK is a novel Shp2 interacting protein 
 
To test the hypothesis that a POSH complex member is a substrate of 
Shp2, a candidate approach using the trapping method was taken. CGNs were 
nucleofected with expression constructs for myc-tagged LZK. To examine the 
effects of Nogo66 stimulation on phosphorylation status of LZK, CGNs were 
plated to PLL or Nogo66. 24 hours after transfection, CGNs were treated with or 
without pervanadate for 30 minutes prior to harvest. Preliminary results of pull 
downs with full length Shp2 RM (catalytically inactive, but non-trapping) or Shp2 
DA/CS (catalytically inactive trapping) showed that stimulation with Nogo66 
results in decreased trapping of LZK (Figure 3.2B, comparison of lane 2 to lane 
4). This result suggests that in neurons LZK is phosphorylated, and upon Nogo66 
stimulation, LZK is targeted for dephosphorylation by Shp2. Consistent with this 
hypothesis, inhibition of endogenous phosphatases with pervanadate treatment 
leads to enhanced Shp2 trapping of LZK upon Nogo66 stimulation, indicating that 
Nogo66 is promoting the association of LZK with Shp2 (Figure 3.2B, comparison 
of lane 6 to lane 8). Collectively, these results show that ectopically expressed 
LZK is trapped by Shp2 in a Nogo66 dependent manner. 
 
3.2.5 In HEK 293 cells, LZK is trapped by Shp2 and is tyrosine 
phosphorylated 
 
To confirm and extend the observations in primary neurons, Shp2 trapping 
experiments were performed in the immortalized and readily transfectable HEK 
293 cell line. 293 cells were transfected with expression constructs for myc-
tagged POSH or LZK and were treated with pervanadate for 30 minutes prior to 
harvest. Pull downs with full length Shp2 RM or Shp2 DA/CS showed that only 
LZK is trapped by inactive Shp2 (Figure 3.3A). These results confirm the results 
observed in CGNs and suggest that HEK 293 cells can be used to examine the 
molecular mechanism of Shp2 trapping of LZK. 
To further analyze the Shp2-LZK interaction, the tyrosine-phosphorylation 






treated with pervanadate, and analyzed by western blot for the presence of 
phosphorylated tyrosine residues. Indeed, when phosphatases are globally 
inhibited, LZK is tyrosine phosphorylated (Figure 3.3B). These results, taken 
together with the ability of LZK to be trapped by Shp2, highlight the potential for 
direct regulation of LZK function by Shp2.  
 
3.2.6 DLK, an additional MLK family member, is also a negative regulator 
of axon length 
 
LZK belongs to the second subfamily of mixed lineage kinases (MLKs), 
which also includes dual leucine zipper kinase (DLK). The two proteins contain a 
kinase domain followed by two leucine-zipper motifs that are separated by a 31 
amino acid spacer. LZK and DLK share 87% homology in their kinase domains 
and 76% homology in their zipper domains (Figure 3.4A) [28, 29]. The N and C-
terminal ends are distinct, however, both proteins associate with POSH and 
activate JNK signaling [28-32]. Since LZK and DLK contain homology, both bind 
to POSH, and activate JNK, we wanted to investigate whether DLK regulates 
axon outgrowth. To address this question in CGNs, RNAi constructs targeting 
DLK were nucleofected into CGNs plated to PLL or Nogo66. Reduction of DLK 
function by RNAi results in enhanced process length identical to the loss of LZK 
function (Figure 3.4B), suggesting DLK is also a negative regulator of axon 
length. To determine whether DLK is downstream of Nogo66 growth inhibition, 
DLK RNAi-expressing neurons were plated to Nogo66. DLK RNAi neurons are 
refractory to growth inhibition by Nogo66 (Figure 3.4B), indicating a role for DLK 
as a signaling protein for myelin-associated proteins. 
The above result suggested that DLK and LZK may be able to 
compensate for each other. To further examine this hypothesis, LZK or DLK were 
ectopically expressed in either DLK or LZK RNAi neurons. Expression of LZK in 
LZK RNAi neurons or DLK in DLK RNAi neurons reverses the long process 
phenotype, indicating specificity of the RNAi constructs (Figure 3.4B). 
Interestingly, LZK was able to complement the loss of DLK and conversely, DLK 






that either kinase can function to regulate axon outgrowth and growth inhibition of 
Nogo66.   
Since both kinases are expressed in CGNs and they both negatively 
regulate axon outgrowth, we hypothesized that loss of both kinases will enhance 
the long process phenotype. Surprisingly, removal of both DLK and LZK function 
by RNAi does not result in further enhancement of axon length (Figure 3.4C).  
This result suggests that DLK and LZK operate on the same pathway or both 
kinases may regulate a downstream, rate limiting step in axon outgrowth. From 
these studies, we conclude that DLK or LZK can modulate axon length, 
responsiveness to Nogo66-induced growth inhibition, and DLK or LZK are able to 
compensate for the loss of each other‟s function when overexpressed. 
 
3.2.7 CGNs from DLK hypomorph mice display long process phenotype 
and are refractory to growth inhibition by Nogo66 
 
To further examine the role of DLK in the cerebellum, DLK hypomorph 
mice were obtained from the Lawrence Holzman laboratory. Previous studies 
using DLK knockout mice demonstrated that DLK-/- mice progressed through 
embryogenesis but died soon after birth [33, 34].  Thus, the Holzman group 
generated a hypomorph that displayed decreased levels of DLK rather than 
complete removal of DLK [35]. The hypomorphs were viable and survived 
through adulthood. At the time of this dissertation, complete phenotypic studies 
of the DLK hypomorph were incomplete; however studies are ongoing in the 
Holzman laboratory. To determine whether constitutively decreased levels of 
DLK in hypomorphs behaved similar to decreasing levels of DLK in CGNs by 
nucleofection with RNAi constructs, CGNs from DLK hypomorph mice and wild-
type litter mate controls were isolated and plated on control substrate or Nogo66. 
CGNs isolated from DLK hypomorph mice show enhanced process outgrowth 
when compared to wild-type CGNs (Figure 3.5). Additionally, DLK hypomorph 
CGNs were refractory to Nogo66, confirming the results seen with DLK RNAi 
constructs (Figure 3.4-3.5). These results suggest that DLK regulates of axon 






3.2.8 Reduced DLK expression does not affect cerebellar morphology 
 
We next wanted to assess the effect of the loss of DLK on the 
development of the cerebellum. The cerebellum is highly ordered, which allows 
for easy identification of cell types and morphology [36]. Briefly the cerebellum is 
organized into a molecular layer that contains the axons of the CGNs and the 
dendrites of the Purkinje cells, a Purkinje cell body layer, and an inner granule 
cell layer, containing CGN cell bodies and the axons of the Purkinje cells. The 
Purkinje cell axons continue into the deep nuclei, relaying further neuronal 
signals. Previous studies in DLK-/- embryos showed that loss of DLK function 
resulted in defects in radial migration and axon projection [34, 37, 38]. 
Additionally, genetic disruption of MKK4, a MAPKK which is activated by DLK, 
results in misalignment of the Purkinje cells of the cerebellum [39]. DLK is 
expressed in both the molecular layer of the cerebellum (CGN location) and in 
the Purkinje cells [40]. Thus, we hypothesized that loss of DLK in the cerebellum 
may also result in changes in granule layer formation or Purkinje cell alignment. 
To examine cerebellar morphology, post-natal day 10 brains were isolated 
from wild-type and DLK hypomorphs and sagittal cryogenic slices were stained 
with calbindin (Purkinje cells) and Hematoxylin and eosin (H&E stain: general 
histology stain). As seen in Figure 3.6, there are no significant differences in 
cerebellar morphology; Purkinje cells were aligned correctly and granule layers 
were of comparable thicknesses in the DLK hypomorph (D-F) compared to wild-
type (A-B). This was not unexpected as the mice did not exhibit any traditional 
cerebellar behavioral deficits such as circling or altered gait (data not shown). 
There may be changes in morphology at a smaller scale, such as the number of 
synaptic connections between CGNs and Purkinje cells and/or aberrant axon 
growth; however we were unable to visualize these differences with our current 
tools. It is also possible that LZK expression in the cerebellum is able to  
compensate for the loss of DLK, preventing any significant morphological 







valuable insight into the role of each kinase during development and after 
neuronal injury. 
 
3.2.9 Unlike LZK, DLK is not able to compensate for the loss of PirB in 
CGNs 
 
Our findings indicate that DLK and LZK are negative regulators of axon 
length and are members of the signaling pathway downstream from Nogo66-
induced growth inhibition. Thus, we asked whether DLK is downstream of the 
Nogo66 receptor, PirB. To address this question, DLK or LZK constructs were 
expressed in PirB RNAi CGNs. As seen previously, overexpression of LZK in 
PirB RNAi expressing neurons reverses the long process phenotype observed 
with a loss of PirB function (Figure 3.7A). However, ectopic expression of DLK 
fails to complement the loss of PirB or restore growth inhibition by Nogo66 
(Figure 3.7A). This result was unexpected given the previous results suggesting 
that either kinase can suppress the loss of the other when overexpressed in 
CGNs and the result that  both mediate Nogo66 signaling (Figure 3.4B). It is 
possible that DLK is not downstream of PirB and is relaying Nogo66 signaling 
through a distinct signaling pathway. An alternative hypothesis is that DLK is 
regulated by PirB to be incorporated into the MAI signaling pathway, and 
therefore, a loss of PirB prevents DLK incorporation and subsequent function in 
regulating axon outgrowth. 
 
3.2.10 DLK is not trapped by Shp2 
 
LZK is trapped by Shp2 and Shp2 mediates downstream signaling from Nogo66 
and PirB. Therefore, we hypothesized that DLK is regulated in a distinct method 
from LZK, allowing for the selection of LZK in the NogoA-PirB-POSH pathway. 
To assess this hypothesis, Shp2 trapping experiments with overexpressed Myc-
DLK in HEK 293 cells were performed. Following pervanadate treatment, unlike 
LZK, DLK is not trapped by Shp2 (Figure 3.7B). This result suggests that DLK is 






not a substrate of Shp2. Collectively, these results suggest that DLK and LZK are 
both negative regulators of axon outgrowth, yet LZK is specific to the PirB-Shp2-
POSH pathway.  The mechanism of regulation of DLK/LZK function is still poorly 
understood and it will be interesting to determine how the neuron distinguishes 
between the kinases and how DLK is relaying Nogo66 inhibitory signals.  
 
3.2.11 POSH is a convergence point for MAI signaling 
 
The PirB receptor binds all three MAI family members, therefore we 
hypothesized that the POSH complex mediates inhibitory signals from MAG as 
well as NogoA. To address our hypothesis, CGNs were nucleofected with 
control, POSH, and PirB RNAi constructs and plated to PLL, Nogo66, and MAG. 
Loss of PirB function relieves growth inhibition mediated by MAG, similar to what 
we previously observed for Nogo66 (Figure 3.8). Consistent with our hypothesis, 
POSH RNAi expressing CGNs are also refractory to growth inhibition by MAG. 
This result suggests that POSH is a convergence point for MAI signaling. 
Collectively, the studies presented here highlight the importance in characterizing 
the molecular signaling mechanism of the POSH complex as targeting the POSH 
complex may be an efficacious strategy to enhance axonal regeneration in the 
damaged CNS. 
 
3.3 Discussion  
 
Studies from our laboratory have revealed a role for the POSH complex, 
composed of LZK and Shroom3, as downstream components of the NogoA-PirB 
pathway mediating axon growth inhibition [8, 9]. However, the signaling 
mechanism from PirB to the POSH complex was not known. In these studies, we  
define a role for Shp2 as a transmitter of NogoA mediated inhibitory signals to 
the POSH complex and suggest that Shp2 operates, at least in part, through the 
regulation of LZK function (Figure 3.9). We found that the phosphatase activity of 









downstream dephosphorylation event may be required for Nogo66 signaling. 
Consistent with this hypothesis, we demonstrated that upon Nogo66 stimulation 
of CGNs there is enhanced Shp2 trapping of tyrosine phosphorylated proteins 
and we identified LZK, but not POSH, as a potential Shp2 substrate. 
Interestingly, we show that DLK, a MLK family member, is a negative regulator of 
axon length and relays Nogo66-mediated growth inhibition. Additionally, ectopic 
expression of DLK can overcome the loss of LZK. However, DLK cannot 
suppress the PirB RNAi phenotype and is not trapped by Shp2, indicating DLK 
and LZK might undergo distinct regulation to facilitate their function. In summary, 
our studies suggest a model in which, in the absence of Nogo66 signaling, LZK is 
phosphorylated preventing its function in an unknown mechanism. Nogo66-PirB 
mediated inhibitory signals facilitate the dephosphorylation of LZK by Shp2 
promoting LZK function to inhibit axon length.  Collectively, the studies presented 
here further define the intracellular signaling pathway downstream from NogoA. 
Our studies indicate that POSH is a convergence point for MAI signaling. 
Reduction of POSH function by RNAi allows axonal outgrowth on Nogo66 and 
MAG. The PirB receptor binds all three MAIs and its function is required for 
growth inhibition, therefore we hypothesize that POSH is also relaying inhibitor 
signals from the third MAI, OMgp. There are additional receptors for MAIs and 
we are specifically interested in determining if the Nogo66 receptor, NgR1, is 
also signaling through POSH. NgR1 also binds all three MAIs and removal of 
NgR and PirB functions provides enhanced growth on myelin [3, 13, 17, 41]. 
Therefore, it is possible that they work in concert or on converging pathways to 
mediate inhibitory signals. If POSH is found to be a convergence point for all 
three MAIs and their receptors, strategies to block POSH function or complex 
formation could provide more efficacious regeneration of axons after injury or 
disease than targeting only one MAI or receptor. 
The findings that Shp2 relays signals from NogoA through PirB and the 
requirement of its phosphatase activity suggest that Shp2 is a critical component 
of the NogoA signaling pathway.  Additionally, these studies show that Nogo66 
stimulation induces the trapping of several tyrosine phosphorylated proteins by 
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Shp2. This suggests that Shp2 has multiple substrates upon Nogo66 stimulation. 
Recently, it has been shown that upon MAG stimulation, Shp2 associates with 
PirB, binds to the tropomyosin receptor kinase B (TrkB) receptor, and promotes 
dephosphorylation of TrkB after activation by BDNF stimulation [23]. Thus, it 
appears that MAG may inhibit axon growth by promoting the deactivation of 
growth-promoting pathways. Shp2 has also been shown to dephosphorylate 
ROCK, promoting its activation[42]. Hence, TrkB or ROCK could be two of the 
proteins whose association with Shp2 is enhanced following Nogo66 stimulation. 
Analysis of Shp2 associated proteins by mass spectrometry from neuronal cell 
cultures would allow for identification of these substrates. It would also be 
interesting to determine whether inhibitory cues by MAG or NogoA promote Shp2 
action on distinct substrates and how this links to POSH complex function. 
Our studies indicate that Nogo66 stimulation promotes the trapping of LZK 
by Shp2.  The mechanism behind LZK phosphorylation is not known. It is 
possible that LZK is phosphorylated by a growth promoting pathway to keep LZK 
from inducing growth inhibition.  It is also possible that changes in 
phosphorylation status affect the localization or stability of LZK. LZK forms 
dimers to facilitate activation and requires the presence of POSH to relay axon 
growth inhibition [15, 28]. Therefore, we hypothesize that phosphorylation of LZK 
prevents dimerization or association with POSH. Experiments to map the site of 
phosphorylation may help determine how phosphorylation is affecting LZK 
function. 
Our analyses of DLK and LZK reveal that both kinases are negative 
regulators of axon growth and can mediate growth inhibitory signals from 
Nogo66. Thus, it will be interesting to determine whether additional MLK family 
members (MLK1-4 and ZAK) can also regulate axon outgrowth. However, LZK, 
but not DLK, is able to complement the loss of PirB and is trapped by Shp2, 
indicating that there is differential regulation of MLKs promoting their function in 
distinct signaling pathways. Our results suggest that LZK is somehow 
preferentially selected over DLK to relay inhibitory signals from PirB. It is possible 
that association with Shp2 is sufficient to select LZK rather than DLK. DLK may 
91 
 
function in a distinct NogoA growth inhibitory pathway, perhaps from an 
unidentified Nogo66 receptor. It is also possible that DLK may require the 
presence of PirB to allow DLK to function, perhaps in a feed forward mechanism, 
and subsequently DLK would not be activated in the PirB RNAi neuron.  
Finally, the DLK hypomorph studies suggest the loss of DLK does not affect 
Purkinje cell morphology or general cerebellar cellular organization. However, we 
did not examine differences in granule cell axon projection or changes in synaptic 
connections between granule cells and Purkinje cells. Thus, there may be 
differences between the DLK hypomorph and wild-type mice that we were not 
able to observe. Further animal studies, using conditional, double DLK/LZK 
knockouts along with a more in-depth phenotypic analysis would address 
functional redundancy of DLK or LZK and their role in development.  
 MAIs are a major impediment to regeneration and functional recovery of 
the injured CNS. The results presented by these studies demonstrate a signaling 
pathway downstream of NogoA composed of the receptor PirB, Shp2, LZK and 
POSH. Combined with our previous studies, which also showed the involvement 
of Shroom3 and ROCK in this signaling pathway, our studies delineate a novel 
intracellular signaling pathway downstream of NogoA. Additionally, these studies 
indicate that POSH is a convergence point for MAI signaling, highlighting the 
importance of POSH as an inhibitory axon outgrowth molecule. The findings 
presented here increase the knowledge of intracellular signaling mechanisms 
impeding neuronal growth in CNS. Our results also highlight that blocking the 
function of the POSH complex may promote enhanced axon outgrowth, plasticity, 
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3.5 Materials and Methods 
3.5.1 Antibodies and Reagents 
 
For axon outgrowth assays, cells were stained with anti-green fluorescent 
protein (GFP) rabbit primary antibody (Invitrogen) and Alexa Fluor 488 goat anti-
rabbit secondary antibody (Molecular Probes). For western blots the following 
primary antibodies were used: mouse anti-myc (9E10: purified from hybridomas), 
mouse anti-phosphotyrosine (Millipore), rabbit anti-actin (Sigma), rabbit anti-GFP 
(Invitrogen), and High Sensitivity NeutrAvidin-HRP (Pierce). Secondary 
antibodies used were: Goat Anti-Rabbit IgG Horseradish Peroxidase  (HRP) 
Conjugate (BioRad) and Goat Anti-Mouse IgG Horseradish Peroxidase  (HRP) 
Conjugate (BioRad). MAG-Fc (R&D Systems) was diluted to 100µg/mL in PBS 
and stored at -20°C. 
 
3.5.2 Expression Constructs and RNAi 
 
pUI4-SIBR-GFP is a short interfering RNA (siRNA) expression vector that 
co-expresses the GFP protein and a siRNA from an intronic expression cassette 
(the SIBR cassette) based on the miR-155 microRNA precursor [43]. For each 
siRNA, a pUI4-SIBR-GFP vector expressing one to four identical tandem copies 
of the siRNA SIBR cassette was constructed. POSH-6, luciferase (a functional 
control RNAi vector), PirB-874, LZK-1, LZK-2 are previously described [8, 9]. The 
sequence of DLK siRNA is 5‟ UUAUUCGGUAAUUGGUCAGGGG 3‟. CS2+MT 
POSH and CS2+NFLAG-LZK are described previously [8, 9, 44]. CS2+Myc-LZK 
was subcloned from CS2+NFLAG-LZK using BglII and EcoRI as cloning sites. 
CS2+NFLAG-DLK and CS2+Myc-DLK were subcloned from pcDNA3-DLK, a gift 
from Lawrence Holzman. CS2+3xHA-Shp2 and CS2+3xHA-Shp2 CS were 
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subcloned from pcDNA3+Shp2 and pcDNA3+Shp2 CS, generous gifts from Dr. 
Christin Carter-Su. Constitutively active CS2+3xHA-Shp2 E76K was constructed 
by site-directed mutagenesis, GAG being converted to AAG, substituting 
glutamate 76 to lysine.  Phosphatase dead CS2+3xHA-Shp2 E76K/R465M and 
CS2+3xHA-Shp2 R465M was constructed by site-directed mutagenesis, CGG 
being converted to ATG, substituting arginine to methionine. The Shp2 trapping 
mutant D425A/C459S was constructed by site-directed mutagenesis, GAC being 
converted to GCC, substituting aspartate to alanine. Full length and the isolated 
phosphatase domain (PTP) of wild-type Shp2, the DA/CS trapping mutant, and 
catalytically inactive Shp2 R465M were subcloned into the bacterial expression 
construct pGST3. C-terminally tagged POSH-biotin binding domain was 
constructed by subcloning full length POSH into pEBB-cTB [45] using BamHI and 
NotI restriction sites. 
 
3.5.3 Preparation of recombinant proteins 
 
GST-Shp2 PTP WT, GST-Shp2 PTP DA/CS, GST-Shp2 RM, and GST-
Shp2 DA/CS were produced in Escherichia coli using a pGST3 expression 
system. Briefly, E.coli cells were grown at 37°C until an OD600 of 0.8 was 
reached.  Cells were induced overnight at 4°C with 0.3mM IPTG and lysed by 
sonication in PBS+ (PBS, 100µM PMSF, 14µg/mL aprotinin, 0.1% β-
mercaptoethanol, 1µM leupeptin, 1µM pepstatin). Triton X-100 was added to the 
lysate at 1% of the final volume. Lysates were incubated with prewashed 
glutathione agarose (Pierce) for 1 hour at 4°C and washed three times in PBS+ 
with 300mM NaCl + 1% Triton X-100. The purified proteins, immobilized to the 
beads, were stored in PBS+ with 25% glycerol at -20°C.  Purification of His-







3.5.4 Cerebellar granule neurons (CGNs) 
 
4-well glass chamber slides or 12-well plates were coated for 4 hours with 
10 µg/ml poly-L-lysine then overnight with 2µg/ml laminin (Invitrogen) or 
overnight at 4°C with laminin+control His-SUMO (2.5µg /cm2), laminin+His-
SUMO Nogo66 (2.5µg /cm2), or laminin+MAG-Fc (500ng/cm2).  After overnight 
incubation, unbound substrates were removed by rinsing with PBS. CGNs were 
isolated from the cerebellum of post-natal day (P) 8 mice as described [46]. 
CGNs were transfected using AAD-1001 Nucleofector (Amaxa Biosystems) set 
to program O-03. CGNs were nucleofected with a total of 6µg of DNA: 4.5µg of 
pUI4 vector and 1.5µg of empty vector or CS2+3xHA-Shp2 E76K, CS2+3xHA-
Shp2 E76K/RM, CS2+NFLAG-LZK, or CS2+NFLAG-DLK. CGNs isolated from 
wild-type and DLK hypomorph mice were plated with a final concentration of 
100,000 cells/cm2. Cells were fixed in 3.7% formaldehyde 24 hours post-
nucleofection. Cells were stained with an anti-GFP primary antibody (Invitrogen) 
and Alexa Fluor 488 goat anti-rabbit secondary antibody (Molecular Probes).  
 
3.5.5 Measurement of process length 
 
Process length was measured as described previously [8, 9]. Briefly, using 
the box function in the MicroSuite imaging software version 5.0 (Olympus, Tokyo, 
Japan), the longest process per cell for all the cells within the box was measured. 
Results are presented as average process length, determined from three 
independent nucleofections with an average of 120 neurons measured per 
experiment per condition. Statistical significance was assessed using the 
Students t-test. All measurements of GFP-positive neurons from three 
independent nucleofections were included in the t-test, except for Figure 3.8 






3.5.6 Shp2 trapping assays 
 
In Figure 3.2A, 24 hours prior to harvest 4-10cm dishes of 100,000 
CGNs/cm2 were treated with or without 100µM pervanadate and/or 2.5µg/cm2 
Nogo66. Cells were harvested in Triton IP buffer (10mM HEPES pH 7.4, 2mM 
EDTA, 50mM NaF, 1% Triton X-100, 1mM PMSF, 150mM NaCl, 0.01% 
Aprotinin, 1mM Na3VO4) and incubated with 20µg of GST-Shp2 PTP WT, GST-
Shp2 PTP DA/CS, GST-Shp2 RM, or GST-Shp2 DA/CS immobilized on 
glutathione agarose overnight at 4°C. Beads were washed 3 times with Triton IP 
buffer and resuspended in 40µL of 2x Sample Buffer. 10µL of sample were 
separated on a SDS-PAGE gel followed by western blot analysis for tyrosine 
phosphorylated proteins.  In Figure 3.2B, 7x106 CGNs were nucleofected with 
5µg of CS3+MT LZK and 1µg of CS2+eGFP. Each nucleofection was split onto 
2-60mm dishes coated with PLL or PLL+2.5µg/cm2 of Nogo66, for a total of 4 
nucleofections and 8-60mm dishes. Prior to harvest, CGNs were treated with or 
without 100µM pervanadate and harvested in Triton IP Buffer. Shp2 pull downs 
proceeded as described above. 
In HEK 293 cells, 32,000 cells/cm2 were transfected with 3ug of DNA of 
CS3+MT POSH, CS3+MT LZK, or CS3+MT DLK. 24 hours after transfection, 
cells were treated with or without 100µM pervanadate for 30 minutes, harvested 
in Triton IP Buffer, and incubated with 20µg of GST-empty, GST-Shp2 RM, or 
GST-Shp2 DA/CS immobilized on glutathione agarose for 1 hour at 4°C. Beads 
were washed 3 times with Triton IP buffer and resuspended in 40µL of 2x 
Sample Buffer. 10µL of sample were separated on a SDS-PAGE gel followed by 
western blot analysis for the myc-epitope tag. 
 
3.5.7 DLK mice/staining 
 
All procedures involving the use of mice were approved by the University of 
Michigan committee on the Use and Care of Animals (UCUCA). DLK hypomorph 
transgenic mice were obtained from Lawrence Holzman and maintained on a 
C57BL/6J background (unpublished data). The DLK transgene was detected 
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using forward primer 5‟-GGTGGTTGTTATCATAGTTCCATCATG-3‟ and reverse 
primer 5‟-GCTAGTCATGGAGTAGTAGG-3‟. Whole brains from P10 mice from 
wild-type and DLK hypomorph mice were harvested and fixed in 4% 
paraformaldehyde overnight at 4°C. Brains were embedded in Optimal Cutting 
Temperature embedding medium (Sakura Finetek, Torrance, CA), cryosectioned 
(15µm) and stored at -80°C. For Calbindin staining, slides were fixed in 4% 
paraformaldehyde, blocked for 2 hours in Tyramide signal amplification (TSA) kit 
block (Invitrogen), and stained overnight at 4°C with mouse anti-Calbindin 
(Swant) at 1:10,000. Slides were developed using DAB reagent (Sigma), 
followed by mounting with mounting media. Hematoxylin and eosin stain was 
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The adult mammalian central nervous system (CNS) is limited in its ability 
to regenerate or replace the axons of neurons lost in response to injury or 
disease. A crucial contributor to this lack of regeneration is myelin and its three 
associated proteins termed myelin associated inhibitors (MAIs): Myelin-
associated glycoprotein (MAG), NogoA, and Oligodendrocyte-myelin glycoprotein 
(OMgp) [1, 2]. Blocking the function of MAIs, with antibodies or receptor 
antagonists promotes axon growth and plasticity, and results in enhanced 
functional recovery after stroke or spinal cord injury in rodent models [3-10]. 
Thus, functional recovery after CNS injury is limited by MAIs, and small molecule 
compounds that can circumvent MAI inhibition are likely to enhance functional 
recovery after stroke or spinal cord injury. 
A complicating factor in developing small molecules for CNS regeneration 
is the complexity of signaling at the neuronal cell surface. There are multiple and 
overlapping receptors for MAIs, and targeting individual MAIs may not fully 
relieve growth inhibition [11-17]. A complementary and perhaps more efficacious 
strategy to enhance axon growth after injury might be to target MAI intracellular 
signaling pathways. We have previously shown that the POSH complex 
consisting of LZK and Shroom3 is downstream of NogoA and its receptor PirB 
[18]. Loss of function of POSH, or any one of the POSH associated proteins, 
leads to enhanced process growth and refraction to inhibition by NogoA. POSH 
is also downstream of MAG (Chapter 3, Figure 3.8) suggesting that the POSH 
complex is a convergence point for MAI signaling. Thus, we sought to identify 
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chemical inhibitors that target specific protein-protein interactions of the POSH 
complex, and we propose that these inhibitors will circumvent NogoA or MAG-
mediated growth inhibition. 
Correct formation of protein-protein interactions (PPIs) is required for 
nearly all cellular processes and a protein‟s function can directly rely on its 
interacting protein. Indeed, the role of a signaling protein in the CNS can be 
distinct from its role elsewhere in the body [19]. Targeting the enzymatic activity 
of a protein will affect all signaling pathways in which the protein is involved, 
potentially leading to severe side effects. On the other hand, inhibiting the ability 
of an enzyme to bind a specific substrate would allow the overall activity of the 
enzyme to persist, but limit the downstream effects. Furthermore, specifically 
disrupting the interaction of an enzyme with a substrate that only occurs in the 
CNS would be an even more efficacious drug development strategy.  Thus, there 
is much interest in targeting non-enzymatic, PPIs for therapeutic purposes as this 
strategy may limit off target side effects elsewhere in the body. 
Current strategies to inhibit PPIs involve the use of antibodies, dominant 
negative peptides, or antisense constructs. However, all of these strategies are 
expensive to manufacture, lack oral bioavailability, and in the case of antibodies, 
are not cell permeable [20]. Therefore, strategies for treating spinal cord or stroke 
injury have relied on implants, which secrete antibodies, or direct injection of 
therapeutics into the spinal cord tract. Thus, the use of small “drug-like” 
compounds to target intracellular PPIs has attracted the attention of scientists 
both in the pharmaceutical industry and academia as tools to develop more 
efficient and cost effective therapies.  
Development of chemical inhibitors of PPIs has proven more difficult than 
targeting the enzymatic activity of a protein. The major obstacle in targeting PPIs 
is the sheer size and geometry of the interaction interface. The contact surface 
involved in a PPI is typically large (~800-3,000 Å), while the contact surface of a 
protein-small molecule is small (~300-1000 Å) [21, 22]. Also, the interface of two 
interacting proteins may be flat compared to the grooves and pockets present at 
the active site of an enzyme or at the hydrophilic surface of a protein, thus not 
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providing a ideal surface for small molecule binding [21, 23, 24]. Additionally, 
unlike most enzymatic proteins and receptors, most PPIs do not have natural or 
known small molecule partners, and rational design of chemical inhibitors without 
structural knowledge of a PPI is difficult. Lastly, a surprisingly common inhibitory 
mechanism has been discovered in which small molecules inhibit the PPI without 
binding to the interaction site. Examples of these include: allosteric inhibitors, 
denaturants, or amphipathic small molecules that can form micelles around a 
protein, preventing the interaction from forming [25-28]. For example, DnaK is a 
molecular chaperone whose ATPase activity provides energy for bacterial 
chaperone machinery and complex formation of DnaK with DnaJ and GrpE are 
essential for the ATPase activity of DnaK [29, 30].  In a high-throughput screen 
for inhibitors of the DnaK-DnaJ interaction, myricetin was identified [31]. 
However, it was determined that myricetin bound to DnaK at a site 20-30Å away 
from the DnaJ binding region and structural studies support the hypothesis that 
myricetin binding may alter the confirmation of DnaK in a way that prevents DnaJ 
binding [31].  
A breakthrough in targeting PPIs occurred when alanine scanning 
mutations along the interaction site of PPIs led to the discovery of „hot spots‟ on 
protein interaction surfaces [32, 33]. Hot spots are small regions of the PPI that 
contribute a disproportionate amount to the binding energy of the PPI. For 
example, alanine scanning revealed that glutamate 62 and phenylalanine 42 on 
the cytokine IL-2 are critical residues for its association  with its receptor IL-2Rα 
[34]. Small molecules were discovered which bound within this region and 
tethering these molecules together provided a more potent inhibitor to disrupt the 
cytokine-receptor interaction [35]. Thus, identifying hot spots on a protein 
provides knowledge for rational design of chemicals to enhance the disruption of 
PPIs with small molecules.  
In the absence of „hot spot‟ information or structural knowledge of the PPI 
interface, high-throughput screening (HTS) is often performed to efficiently 
identify chemical inhibitors. There are many approaches to the discovery of small 
molecule inhibitors of PPIs that are amenable to HTS. The most direct and 
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common method is a competitive binding assay in which one or more of the 
proteins is labeled, such as enzyme linked immunosorbant assay (ELISA) or 
Forster resonance energy transfer (FRET). In the following studies, we describe 
the development of a modified ELISA platform for the identification of chemical 
inhibitors of the POSH complex, specifically the Shroom3-ROCK interaction. 
Using this platform, 20,000 small molecules were screened in the Center for 
Chemical Genomics (CCG) at the University of Michigan. Significantly, 36 
inhibitors of the Shroom3-ROCK interaction have been confirmed by dose 
response. Further validation and characterization of these compounds will 
provide valuable tools to examine the importance of PPIs in the POSH complex 
and their role in growth inhibition mediated by MAIs.  
 
4.2 Results 
4.2.1 The Shroom3-ROCK interaction is direct and biologically 
significant 
 
The aim of this study is to identify chemical inhibitors of the POSH 
complex that relieve axon growth inhibition on MAIs. Thus, the chosen protein-
protein interaction (PPI) must be both direct and biologically significant. The 
ASD2 domain of the POSH interacting protein Shroom3 is required for Shroom3 
to regulate process outgrowth inhibition [36]. ROCKI and II interact with the 
ASD2 domain of Shroom3 through regions denoted R1C1 and R2C1, 
respectively [37]. In epithelial cells, ectopic expression of R1C1 or R2C1 acts in a 
dominant negative manner to block apical constriction by interfering with the 
ability of endogenous ROCK to bind Shroom3 [37]. To determine whether ROCK 
functions with Shroom3 to inhibit axon outgrowth, P19s were transfected with 
R1C1 and its effects on process length were assessed. Process length is 
enhanced in R1C1 expressing neurons relative to control, suggesting that 
Shroom3 acts through ROCK to inhibit process outgrowth (Figure 4.1A). 
Additionally, inhibition of ROCK with the pharmacological inhibitor Y-27632 






previous studies that demonstrate a role for ROCK as an inhibitor of axon 
outgrowth and regeneration after injury [38-40]. This result also suggests that 
ROCK can mediate growth inhibition in both a Shroom3 dependent and 
independent mechanism. These results indicate process outgrowth inhibition is 
mediated, in part, through the Shroom3-ROCK interaction.  
In order for the Shroom3-ROCK interaction to be an ideal candidate for 
chemical inhibition, the interaction needs to be direct. Therefore, bacterial 
expression constructs for the individual domains ASD2, R1C1, and R2C1 were 
generated (Figure 4.1B). GST-ASD2 and HisSUMO-R1C1 were purified from 
Escherichia coli and pull-down analysis was performed. HisSUMO-R1C1 bound 
to GST-ASD2 and the interaction was direct and specific (Figure 4.1C). 
Subsequent experiments with R2C1 indicate that the ASD2-R2C1 interaction is 
also direct and specific (data not shown). These results indicated that the ASD2-
Rho kinase interaction is an attractive site for interference by a small molecule 
and, combined with the result that the Shroom3-ROCK interaction is biologically 
significant, highlights the PPI as a plausible target for chemical inhibition. 
 
4.2.2 Development of Fluorescence Quench Assay (FQA)  
 
To initiate a screen for potential inhibitors of the Shroom3-ROCK 
interaction, we investigated several high-throughput methodologies. Non-
fluorescent Forster resonance energy transfer (FRET) is a common methodology 
to study interactions between proteins. FRET is a non-radiative energy transfer 
that occurs when the emission spectrum of a donor overlaps with the absorption 
spectrum of an acceptor [41]. As the donor and acceptor are brought within a 
certain distance of one another (<10nm), the interaction is characterized by a 
reduction in donor fluorescence and an increase in acceptor fluorescence. 
However, FRET is not ideal when performing binding titrations due to an overlap 
of the acceptor and donor fluorescence spectra [42]. Therefore, non-fluorescent 
acceptors have been employed to remove the need for spectral isolation, 
improve the sensitivity of the assay, and simplify binding experiments [31, 42].  
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A Fluorescence Quench Assay (FQA) which employs these non-
fluorescent acceptors was initially chosen to examine the Shroom3-ROCK 
interaction [31, 42]. FQA was chosen based on the fact that it is highly amenable 
to HTS, as the assay only entails mixing of the two proteins with no wash steps 
or addition of detection reagents. FQA requires the labeling of one protein with a 
fluorescence molecule and the other with a quencher. An interaction is visualized 
by a quench in fluorescence. This is due to the fluorescent-tagged protein 
coming within distance of the protein tagged with the quencher. To develop the 
reagents necessary for this assay, GST-ASD2 was labeled with the fluorescent 
donor Alexa-488 (emission 525nm), subsequently referred to as Alexa-ASD2. 
Additionally, HisSUMO-R1C1 was labeled with Black Hole Quencher-10 (BHQ-
10), a FRET acceptor that absorbs strongly around 507nm, henceforth referred 
to as BHQ-R1C1. When Alexa-ASD2 comes into contact with BHQ-R1C1, the 
fluorescence emission from the Alexa label should be quenched (Figure 4.2A).  
Inhibition of this PPI by a chemical or with unlabeled R1C1 will result in a loss of 
quenching (Figure 4.2A).  
To characterize the Alexa-ASD2 and BHQ-R1C1 interaction, we first 
varied the time of incubation and monitored the percent quench in fluorescence. 
Using the FQA, the apparent Kd was calculated to be 1 ± 0.1µM (data not 
shown). However, the change in fluorescence was saturated almost immediately 
(less than five minutes) following the addition of the two proteins, and this signal 
did not change even up to two hours (Figure 4.2B). Thus, this rate of association 
may be too fast for identifying inhibitors effectively by HTS. Further, as there are 
no known chemical inhibitors of the Shroom3-ROCK interaction, unlabeled R1C1 
was used as a positive control for blocking the ASD2-R1C1 interaction. A 
competition experiment with increasing concentrations of unlabeled R1C1 was 
performed to determine whether the observed quenching was due to specific 
ASD2-R1C1 binding. Surprisingly, unlabeled R1C1 was unable to compete with 
BHQ-R1C1 for association with Alexa-ASD2 (Figure 4.2C). Additionally, 
switching the orientation of the labels, BHQ-ASD2 and Alexa-R1C1, did not allow 






also observed quenching with labeled BHQ-GST epitope tag. BHQ-GST 
quenched Alexa-R1C1 fluorescence to nearly the same extent as BHQ-ASD2, 
suggesting that a non-specific interaction is responsible for quenching (Figure 
4.2D). These results clearly indicate that the observed quench is due to non-
specific association of GST, and not due to a specific ASD2-R1C1 interaction.  
Together with the lack of time dependent quenching, these data suggest that 
non-specific binding is affecting our assay. 
 To verify that the Alexa- or BHQ-tagged proteins were still capable of 
interacting, pull-down analysis was performed. Surprisingly, the proteins were no 
longer able to associate, suggesting that the Alexa and BHQ tags were 
interfering with the interaction (data not shown). Given this data, we further 
proposed that the addition of the tags may result in a conformational change or a 
decrease in solubility. To investigate this hypothesis, size exclusion 
chromatography was performed on BHQ-ASD2 and the fractionation pattern of 
protein was analyzed by SDS-PAGE. BHQ-ASD2 has an expected molecular 
weight of 73Kda and size exclusion chromatography showed that BHQ-ASD2 
eluted off the column in fractions 5-17, with the highest amount of protein in 
fraction 9-13. This is consistent with a molecular weight of 400-600kda (Figure 
4.2E). Similar data was seen for Alexa-R1C1, which has an expected molecular 
weight of 38kDa and eluted off the column in fractions 13-19, indicating a 
molecular weight of 150-400kDa (data not shown). These results indicate that 
application of the Alexa and BHQ tags to ASD2 or R1C1 results in protein 
aggregation. Collectively, these studies suggest that an HTS platform that 
requires labeling of R1C1 or ASD2 with a fluorescent tag may not be plausible for 
identifying chemical inhibitors of our PPI. Therefore, we next pursued an ELISA-








4.2.3 Development and optimization of ELISA platform 
4.2.3.1 Selecting a detection method for ELISA assay 
Although initial studies were carried out with ROCKI, ROCKII is the 
prominent isoform in the brain and displays higher affinity to Shroom3; therefore 
all further studies were performed with R2C1, the Shroom3 binding region of 
ROCKII (Figure 4.1B) [37]. The ELISA platform requires that one protein be 
immobilized or captured on a microplate, followed by addition of the second, 
interacting protein. Toward this goal, we took advantage of a high-binding 
polystyrene surface on clear 96 or 384-well microplates, which allowed GST-
ASD2 to be directly immobilized on the surface. Briefly, our initial ELISA protocol 
(Figure 4.3A, left) began with immobilization of GST-ASD2 on the 96-well 
microplate surface, followed by addition of HisSUMO-R2C1. There are no known 
antibodies against ASD2 or R2C1, therefore to detect the proteins we used 
antibodies directed against the epitope tags. Thus, binding of HisSUMO-R2C1 
was detected using an anti-SUMO antibody, followed by application of an HRP-
conjugated secondary antibody. Detection of HRP was carried out using turnover 
of the HRP substrate tetramethylbenzidine (TMB, absorbance at 450 nm). 
HisSUMO-R2C1 bound to GST-ASD2 in a promising dose-dependent manner 
(Figure 4.3B). However, even at a 20:1 ratio of ASD2:R2C1, the maximum signal 
was < 1 absorbance units at 450nm, suggesting the need for a more sensitive 
detection system. 
In order to enhance efficiency and improve the signal-to-noise ratio of the 
ELISA, HisSUMO-R2C1 was biotinylated and detected with NeutrAvidin-HRP 
(Figure 4.3C). The advantage of this detection system is three-fold:  first,  the 
biotin label is smaller than the fluorescent labels (589 Da to 703-885 Da, 
respectively) and,  second, the polyethylene glycol (PEG) linker on the biotin 
label enhances solubility of the protein, preventing the aggregation that was seen 
when the proteins were labeled with the fluorescent tags.  Third, the high-affinity 
biotin-avidin interaction is extremely sensitive and efficient relative to the use of 






the number of steps necessary for detection, making the assay more amenable 
for HTS. As expected, detection using NeutrAvidin-HRP increased the 
absorbance signal over 3-fold, allowing for an enhanced signal-to-noise ratio of 
3.5:0.1 (Figure 4.3A, left). Therefore, all further optimization was performed with 
Biotin-HisSUMO-R2C1 (termed Biotin-R2C1) and was detected with NeutrAvidin-
HRP.  
4.2.3.2 Removal of GST epitope tag and affinity determination 
 
As previously observed in the FQA assay, non-specific binding between 
epitope tags was again observed, despite improvements in signal-to-noise. Using 
the ELISA platform, we determined the apparent Kd for GST-ASD2 and Biotin- 
R2C1 using 0.5µg immobilized GST-ASD2 and varying concentrations of Biotin-
R2C1. The apparent Kd was calculated to be 3.2 ± 0.2 nM (Figure 4.4A). 
However, interaction of Biotin-R2C1 with the same amount of isolated GST 
immobilized on the plate resulted in an apparent of Kd of 290 ± 19 nM (Figure 
4.5A). Additionally, untagged R2C1 was unable to compete with 100ng of Biotin-
R2C1 for binding 0.5µg GST-ASD2 (Figure 4.4B). Together, these data indicate 
that non-specific binding between GST and HisSUMO-R2C1 is contributing to the 
interaction. As a first attempt to remedy this, the concentrations of salt and 
detergent in the wash buffers were varied. We varied Tris, Phosphate, and 
HEPES buffers with amounts of salt, detergent, and carrier protein (data not 
shown). However, no significant reduction in non-specific binding was observed. 
The HTS screen could be run at protein concentrations just at the Kd of the 
specific ASD2-R2C1 interaction (3.2 nM). At this concentration, we do not 
observe non-specific binding of R2C1 to GST (Figure 4.4A). However, the fact 
that we are not able to compete with the ASD2-R2C1 interaction using unlabeled 
R2C1 is more problematic. Collectively, these results necessitate the removal of 
the GST tag altogether. 
Removal of the GST tag by TEV protease digestion did not significantly alter 






 4.4C). Importantly, removal of the GST tag allowed unlabeled R2C1 to compete 
with Biotin-R2C1 for association with ASD2 (Figure 4.4D). Significantly, this is the 
first interaction between ASD2 and R2C1 that could specifically be disrupted by 
titration of an unlabeled competitor. Thus, the ELISA platform using Biotin-R2C1 
and untagged ASD2 is appropriate for screening for chemical inhibitors. 
 
4.2.3.3 Optimization of ELISA platform for 384-well HTS 
 
Prior to optimization of assay conditions and HTS protocol, it is necessary to 
first transition a 96-well assay to a 384-well microplate format for efficient HTS. In 
order to achieve the highest signal-to-noise ratio, we varied concentrations of 
salt, detergent, and carrier proteins in the interaction and wash buffers (Figure 
 4.5A). It was determined that the signal resulting from the ASD2-R2C1 
interaction was highest when in Tris- buffered saline (TBS) supplemented with 
0.05% Triton X-100, 150mM KCl, and 0.5% BSA. The wash buffer that removed 
any remaining background binding was TBS with 300mM KCl and 0.5% Triton X-
100 (Figure 4.5A).  
The stability of a PPI in the presence of DMSO must also be known, as the 
diverse chemical libraries in the CCG are stored in DMSO. For our screen and 
subsequent dose response confirmation, the highest amount of compound that 
may be added to a sample is 2µL, which in our assay volume of 30µL is 6.7% 
DMSO. For the desired compound concentration of 10µM in the primary screen, 
200nL of compound will be added to each well, which is 0.7% DMSO. Therefore, 
the ASD2-R2C1 interaction was monitored in 0-10% DMSO. The ASD2-R2C1 
interaction is unaffected by the presence of DMSO up to a concentration of 10% 
of the final volume of the assay and this lies within the range of our assay (Figure 
4.5B).  
To finalize the screening protocol, the stability of ASD2 immobilized on the 
384-well microplate was determined, as the duration of the assay in screening 
centers such as the CCG is often driven by the rate of compound addition by 






store plates at 4°C. Thus, the stability of immobilized ASD2 was determined at 
25°C from 0.5-6 hours. Immobilized ASD2 is stable at 25°C for up to 2 hours 
without significant loss of signal (Figure 4.5C). After 2 hours, the signal is nearly 
halved, indicating that compound addition followed by R2C1 addition must occur 
within 2 hours. The ASD2-R2C1 interaction is stable up to 8 hours (data not 
shown). Fully optimized conditions and protein concentrations based on these 
collective data are described in detail in the Materials and Methods. 
 
4.2.4 Primary Screen for inhibitors of Shroom3-ROCKII interaction 
 
 The Chem Div 20,000 compound collection from the CCG at the 
University of Michigan was used as the source of the small molecules for the 
primary screen. The collection was chosen based on the availability of 
compounds for potential follow-up and the structural diversity of the compounds. 
Since our target is a protein-protein interaction with no known inhibitors to use as 
reference, it was especially important to screen a library that sampled a large 
amount of chemical space to increase the probability of hits. 
Briefly, 150ng of ASD2 was immobilized on 384-well high-binding plates 
for 16 hours at 4°C prior to the screen. Plates were washed, blocked, and then 
200 nL of chemical compound was added to columns 3-22 for a final 
concentration of 10µM. One compound is added per well with no replicates for 
the primary screen. The concentration of Biotin-R2C1 used in the screen was 
chosen to be 7nM (10ng) which is at the apparent Kd of 7.9 nM. This 
concentration of Biotin-R2C1 was chosen as it yielded an adequate signal for 
detection (~ 1-1.5 absorbance units at 450nm). Also, it is important to screen at 
concentrations at or below the Kd, as an excess of ASD2 or R2C1 in the assay 
could raise the IC50 values of the chemicals above the threshold used to identify 
active compounds, therefore preventing them from being identified as hits [43]. 
Biotin-R2C1 was added to all columns (1-24). The negative control for inhibition 
by a compound, located in columns 1 and 2, was defined as the absorbance 
signal from ASD2 with 10ng Biotin-R2C1 in 0.67% DMSO. As a positive control 
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for inhibition we used unlabeled HisSUMO-R2C1. Thus, in columns 23 and 24, 
the positive control was defined as the absorbance signal with 5µM HisSUMO-
R2C1 and 10ng Biotin-R2C1 (Figure 4.6A-B).  
As an official gauge of signal-to-noise in HTS, a Z-factor (Z‟) is calculated 
using both the positive and negative control terms and the error associated with  
these terms. A Z‟ value between 0.5-1 is considered an excellent assay [44]. In 
our primary screen, the negative and positive controls displayed average signals 
of 1.25 and 0.14 respectively, resulting in an overall average Z-factor of 
approximately 0.74. Data is fit at percentage change in signal relative to the 
negative control (Figure 4.6C). Hits were defined as showing a signal that is 
greater than or equal to 3 standard deviations (3SD) away from the mean 
negative control per individual plate, roughly greater than 20- 30% inhibition (red 
line in Figure 4.6C). In Figure 4.6D, a sample plate is shown as a „heat map,‟ 
where the negative controls (columns 1-2) show no signal (0% inhibition, blue) 
and the positive controls (columns 23-24) represent 100% inhibition (red). A 
representative hit is observed in well A11, yielding inhibition of 53.3% (yellow 
square). Of the 20,000 compounds tested, 180 compounds were identified as 
hits using the 3SD cutoff (hit rate = 0.9%) (Figure 4.6E). The ELISA assay was 
developed to be highly stringent, and non-enzymatic protein-protein interactions 
have proven difficult to inhibit, therefore the low hit-rate was not unexpected.  
4.2.5 Confirmation by dose response 
 
To analyze and further rank initial hits, a primary screen is often followed by 
dose-response characterization. Thus, our 180 compounds proceeded to a round 
of confirmation by dose-response. Briefly, compounds were titrated from stock 
plates of 5mM to concentrations of 3-100µM using the Mosquito X1 in the CCG. 
For the dose-response round of HTS, we used more stringent criteria to define 
compounds as active. Two requirements were used: (1) compounds with 
inhibition greater than 30% compared to the negative control and (2) pAC50 of 










an estimate of the IC50 value (pAC50 = -log (IC50)). From the 180 compounds, 74 
chemicals were identified as active using these dual criteria (Figure 4.7A).  
Additional selection criteria were applied to prioritize the pool of hits. Small 
molecules that yielded less than 60% maximum efficacy (defined as inhibition at 
the highest concentration screened, 100 M) were eliminated, reducing positive 
hits to a collection of 52 compounds. Next, we used additional data available in 
the CCG to eliminate potentially promiscuous compounds. Briefly, we defined the 
number of other protein targets that a compound has hit from previous screens 
as the promiscuity index. Thus, compounds that were identified as hits in greater 
than 22% of screens performed at the CCG were eliminated as promiscuous 
inhibitors of PPIs. Promiscuous molecules may be general inhibitors of PPIs such 
as denaturants or hydrophobic molecules, which form micelles to inhibit PPIs. 
Application of these criteria resulted in 36 chemical inhibitors of the ASD2-R2C1 
interaction (Figure 4.7A). The highest rated compound by our criteria, termed 
Compound A, displayed an IC50 value of 7.3 ± 1.1 µM with a maximum efficacy of 
100% at 35.9 µM (Figure 4.7B). Further, compound A hit only 3.2% of other 
targets screened in the CCG. 
Finally, DataMiner software using Tripos algorithm OptiSim software was 
used to structurally classify and cluster the remaining 36 hits. Interestingly, 
clustering of compounds with 65% structural similarity in scaffold structure 
yielded: 2 clusters of 5, 1 cluster of 4, 1 cluster of 3, 3 clusters of 2, and 13 
unique compounds (Figure 4.7A). Significantly, if a scaffold is found multiple 
times within a screen, it strongly indicates a real disruption to the PPI, rather than 
an artifact. Further, it offers initial data for structure-activity analysis, the next step 
in analyzing a class of small molecule inhibitors. However, a cluster is not 
indicative of equivalent efficacy or potency, as one of these clusters of 5 
compounds yields a range of IC50 values from 11-60 µM (Figure 4.7C). 
Additionally, we only screened 20,000 compounds which is a small collection of 
chemicals and the collection is structurally diverse to begin with; therefore, the 
fact that 13 of the hits did not cluster does not imply that they are less ideal 





In summary, these studies describe a modified ELISA platform that is 
amenable for screening chemical libraries to identify small molecule inhibitors of 
the Shroom3-ROCK interaction. Screening of the 20,000 ChemDiv library in the 
Center for Chemical Genomics (CCG) at the University of Michigan yielded 180 
active compounds of which 74 titrated in dose response. A total of 36 inhibitors of 
the Shroom3-ROCK interaction were selected to proceed to the next stages of 
development through the application of the following criteria: greater than 60% 
efficacy and less than 22% promiscuity (Figure 4.7A). The next step is to 
establish confidence in the structural identity, purity, and activity of our confirmed 
active compounds by repeating the dose-response using fresh powder samples 
with a larger titration, as not all compounds reached maximum/minimum 
inhibition. Compounds that are re-confirmed in dose-response with fresh sample 
will proceed to secondary assay confirmation to ensure that inhibition was not 
due to general interference in the ELISA assay rather than inhibiting the ASD2-
R2C1 interaction. Lastly, active compounds will then proceed to functional 
assays in primary neuronal cells. 
The modified ELISA assay yields an average Z-factor of 0.74. The Z-factor 
is a measure of statistical effect size and is used in high-throughput screening to 
judge whether the response in an assay is large enough to proceed, and also to 
assess the quality of an assay. The Z-factor is determined from the means and 
standard deviations of both the positive and negative controls. An ideal Z-factor 
is 1, 1-0.5 is defined as an excellent assay, 0.5-0 a marginal assay, and anything 
less than 0 suggests there is too much overlap between the positive and 
negative controls to be useful. A Z-factor of 0.74 indicates that our ELISA 
platform is statistically an ideal assay. 
However, relative to more current methods, an ELISA is not an ideal 
platform for high-throughput screening. The ELISA is highly labor intensive with 
multiple additions, incubations, and wash steps. The protocol limits the amount of 
compounds that can be tested per day to 5,000. NIH defines a high-throughput 
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screening platform as one that is capable of 10,000 compounds per day and 
recent advances in technology have allowed for 100,000 compounds per day 
[45]. Therefore, our assay is not considered high-throughput by industry 
standards. Finally, one of our proteins is immobilized on polystyrene. This could 
influence the conformation of the protein and the interaction site. Indeed, there is 
precedent for a difference in affinity between two proteins, depending upon 
whether the interaction is measured on solid-phase or in solution [46]. Therefore, 
inhibitors identified in this platform may not necessarily translate in solution. A 
secondary confirmation assay in solution is discussed below.      
Despite these disadvantages, there exist several benefits of performing an 
ELISA for HTS. The requirement for multiple wash steps removes chemicals with 
low affinity or non-specific binding, creating a highly stringent assay. The wash 
steps also allow for the removal of compound prior to TMB addition, preventing 
potential oxidation by the compound, and as a result, removing potential false-
positive hits. Removal of the compound prior to detection further reduces the 
possibility of false-positive hits because the compound is absent when 
absorbance is read. Thus, any compounds that absorb light at 450 nm will not 
interfere with detection, unlike an assay without wash steps, which would require 
an additional round of hit confirmation to screen for false-positives. In our assay, 
the only potential false-positive hit could occur from a chemical that inhibits the 
biotin-avidin interaction.  
The apparent Kd for the ASD2-R2C1 interaction using the ELISA platform 
was determined to be 7.9 ± 0.9 nM. This is the first time the binding affinity for 
the ASD2-R2C1 interaction has been defined and, surprisingly, this is a high 
affinity interaction. However, several interactions between signaling proteins 
have been calculated in the nanomolar range. For example, the Kd for the Ras-
Raf interaction is 50nM [47]. The Kd for Shroom3-ROCK was determined using 
the isolated interacting domains and it will be necessary to determine the affinity 
of the full length proteins. Additionally, as mentioned, the apparent Kd could also 




The ELISA platform was developed after attempts at labeling ASD2 and 
R1C1/R2C1 resulted in changes in protein solubility and conformation. Labeling 
R2C1 with biotin did not affect solubility, which is likely due to the presence of a 
polyethylene glycol (PEG) linker on the biotin molecule, which can facilitate 
solubility. Current applications for non-enzymatic high-throughput screening 
require either that one protein be labeled with a tag, or that primary antibodies 
are available for at least one of the proteins of interest. Our results with epitope-
tagged ASD2 and R1C1/R2C1, coupled with the lack of primary antibodies to the 
individual protein domains, significantly limit techniques we can employ to further 
examine the Shroom3-ROCK interaction in an efficient way. In addition, there are 
an additional 130,000 purified compounds and 25,000 natural product extracts 
available in the CCG for screening. Therefore, we are currently developing an 
AlphaLISA platform (Perkin Elmer) as a secondary assay for use in confirmation 
of our hits from the primary screen and for further primary screening of these 
additional libraries.  
AlphaLISA is a bead-based technology that uses luminescent oxygen-
channeling chemistry [48]. Donor and acceptor beads with various epitope tags 
are used and the formation of the PPI brings the beads into proximity. Laser 
irradiation of the donor beads generates a flow of singlet oxygen which results in 
chemical events in the nearby acceptor beads resulting in a chemiluminescent 
emission [49]. The AlphaLISA assay provides an assay that is more amenable 
for high-throughput screening, will allow for secondary confirmation of our current 
hits, and additional screening of chemical libraries [50].  
The aim of HTS-assay development was to identify chemical inhibitors of 
the Shroom3-ROCK interaction that will be used as probes to examine PPIs in 
the POSH complex regulating axon outgrowth. Following confirmation in the 
AlphaLISA, primary neuronal cells will be treated with the validated hits and 
changes in axon outgrowth will be examined. An inhibitor of the Shroom3-ROCK 
interaction should yield neurons with enhanced axon length, similar to results 
seen with ectopic expression of the isolated R1C1 domain (Figure 4.1A). The 
Shroom3-ROCK interaction is crucial for growth inhibition mediated by myelin 
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associated inhibitors (MAIs); therefore a validated chemical inhibitor should also 
relieve growth inhibition on MAIs. Following confirmation in the functional axon 
length assays, identified compounds could be translated for use in stroke models 
to determine whether inhibition of the Shroom3-ROCK interaction is sufficient to 
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4.5 Materials and Methods 
4.5.1 Antibodies and reagents 
Primary antibodies used were neuronal β-III-tubulin (Covance Research 
Products), green fluorescent protein (GFP) (Invitrogen), and SUMO from yeast 
(Rockland). Secondary antibodies included Alexa 488 and 594-conjugated 
antibodies (Invitrogen) and Goat anti-rabbit IgG Horseradish peroxidase 
conjugate (BioRad). For the ELISA assays, High Sensitivity NeutrAvidin-HRP 
(Pierce) was used. The ROCK1/2 inhibitor, Y-27632, was purchased from 
Calbiochem. For the FQA assays, proteins were labeled with BHQ-10 carboxylic 
acid, succinimidyl ester (BHQ-10S) (Biosearch Technologies) and Alexa Fluor 
488 Carboxylic Acid, 2,3,5,6 Tetrafluorophenyl ester (Invitrogen). For biotin 
labeling, Pierce EZ-Link NHS-PEO4-Biotinylation Kit (#21455) was used. 
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4.5.2 Expression Constructs 
pUI4-SIBR-GFP luciferase (a functional control RNAi) sequence is 
described previously [36]. pUS2-R2C1 expressing the Shroom3 binding domain 
of human Rock1 (amino acids 726-926) was cloned from human ROCKI. pGST1-
ASD2 (1563-1986aa) was cloned from human Shroom3. ppSUMO-R1C1 was 
subcloned from pUS2-R1C1 using BamHI and NotI as cloning sites. ppSUMO-
R2C1 (698-957aa) was cloned by RT-PCR with RNA isolated from mouse brain.  
4.5.3 Axon outgrowth experiments 
P19 cells, grown in minimal essential medium-α supplemented with 7.5% 
calf serum, 2.5% fetal bovine serum, and penicillin-streptomycin were plated the 
day before transfection to a density of 9 X 103 cells/well of a 12-well dish and 
transfected the next day with 2µg of total DNA (0.75µg of Ngn2, 1.25µg of 
pUI4/UI5 RNAi expression vector). pUS2-R1C1 was transfected at 850ng/12-
well. 4-6 hours after transfection, cells were resplit 1:5 or 1:6 on laminin-coated 
dishes. 18-20 hours later, the cells were transferred into Opti-mem supplemented 
with 1% FBS and penicillin-streptomycin. 72 hours after transfection, cells were 
fixed in 3.7% formaldehyde in PBS and stained for GFP or neuronal markers of 
differentiation.  
4.5.4 Measurement of Process Length 
To measure process length, photographs of fixed, stained neurons were 
captured with a digital camera, and the length of the longest process per cell was 
measured using the polyline function in MicroSuite Special Edition imaging 
software version 5.0. Processes 50µm or greater were measured: 50µm is ~3 
times the length of the cell body. Process length is determined in two or more 
independent experiments for a total of 224-315 neurons measured per condition. 
Similar results for process length measurements are obtained if neurons are 
fixed and stained for GFP or for neuronal markers of differentiation (β-III-tubulin). 
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4.5.5 Preparation of recombinant proteins 
 
GST-ASD2, HisSUMO-R1C1, and HisSUMO-R2C1 were produced in 
Escherichia coli. Briefly, E.coli were lysed by sonication in PBS+ buffer (GST 
purification: PBS with 0.1mM phenylmethylsulfonyl fluoride, 14µg/mL aprotinin, 
0.1% β-mercaptoethanol, 1µM leupeptin, 1µM pepstatin) (His purification: PBS 
with 0.1mM phenylmethylsulfonyl fluoride, 14µg/mL aprotinin, 0.1% β-
mercaptoethanol, 1µM leupeptin, 1µM pepstatin, 25mM Imidazole). Triton X-100 
was added to the lysate at 1% of the final volume. Lysates were incubated with 
prewashed glutathione agarose or HisPur Ni-NTA resin (Thermo Scientific) for 1 
hour at 25°C. Purified protein was eluted 3 times with 1mL of GST elution buffer 
(50mM Tris buffer with 100mM reduced glutathione, pH 8) or His elution buffer 
(PBS+ with 250mM Imidazole). HisSUMO-R1C1 and R2C1 were dialyzed 
overnight at 4°C in PBS and stored in 25% glycerol at -20°C. GST-ASD2 was 
dialyzed for 3 hours at 4°C in PBS with 3 buffer changes. The GST epitope tag 
was removed using His-TeV (S219V)-Arg Protease overnight at a concentration 
of 1µg TeV per 100µg of GST-ASD2. TeV and free GST was removed from 
purified ASD2 by incubation overnight at 4°C with prewashed glutathione 
agarose and HisPur Ni-NTA resin. ASD2 was stored at -20°C in 25% glycerol.  
 
4.5.6 Labeling with AlexaFluor 488 5-TFP and BHQ-10 carboxylic acid 
 
Labeling of GST-ASD2 or HisSUMO-R1C1 with BHQ-10 carboxylic acid 
(Biosearch Technologies) or AlexaFluor 488 5-TFP (Invitrogen) was performed 
as per manufacturer‟s instructions. Briefly, labeling reactions were carried out at 
a 10:1 molar ratio of dye to protein in bicarbonate buffer (100mM NaHCO3, 5mM 
MgCl2, 10mM KCl, pH 9.5). Proteins were labeled for 1 hour at 25°C under a 
constant low vortex. After the incubation, the unreacted dye was removed and 
the buffer was exchanged to PBS (pH 7.4) using ZebaTM Desalt Spin Columns 
(2mL, MWCO= 7000Da) (Pierce). The average extent of labeling for GST-ASD2 
and HisSUMO-R1C1 was determined to be approximately 6.5 fluorophore/dye 
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per protein, respectively, using the ε495= 71,000 M
-1cm-1 (Alexa Fluor 488) and 
ε507= 30,000 M
-1cm-1 (BHQ-10). Labeled proteins were stored at -80°C. 
 
4.5.7 Biotinylation of HisSUMO-R2C1 
 
HisSUMO-R2C1 was biotinylated as described with the NHS-PEO4-
Biotinylation Kit (Pierce). Briefly, biotinylation reactions were carried out at a 20:1 
molar ratio of NHS-PEO4-biotin to HisSUMO-R2C1 in PBS (pH 7.4). HisSUMO-
R2C1 was labeled for 2 hours at 4°C. After the incubation, the unreacted NHS-
PEO4-biotin was removed with buffer exchange in PBS (pH 7.4) using Zeba
TM 
Desalt Spin Columns (2mL, MWCO= 7000Da) (Pierce). The average extent of 
labeling for HisSUMO-R2C1 was estimated to be 4 biotin molecules per 1 mole 
of protein using the HABA assay, a measurement of the extent of biotinylation, as 
per the manufacturer‟s protocol. Biotin-R2C1 was stored at -20°C in 25% 
glycerol. 
 
4.5.8 Pull down assay 
 
5µg of GST or GST-ASD2 and 5µg of HisSUMO or HisSUMO-R1C1 were 
incubated for 1 hour in 10µL prewashed glutathione agarose. Pull-downs were 
washed 2 times in PBS+0.1% Triton X-100 and 1 time with PBS. Proteins were 
eluted from beads with 20µL of sample buffer and 15µL of samples were 
analyzed by SDS-PAGE followed by staining with GelCode Blue (Pierce).  
 
4.5.9 Fluorescence Quench Assay (FQA) 
 
To determine the Kd (Figure 4.2B and C), 250nM of Alexa-ASD2, diluted in 
PBS (pH 7.4), was added to 384-well, black round bottom plates (Corning). BHQ-
R1C1 (20nM-60µM) was added in triplicate to appropriate wells and the samples 
were incubated for 30 minutes, 1 hour, or 2 hours. After incubation, the 
fluorescence at 525nm (excite 480nm, cut-off 515nm) was measured using a 
SpectraMax M5 microplate reader. The results were analyzed by GraphPad 
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Prism 4.0 using a hyperbolic fit with a non-zero intercept 
(∆F=∆Fmax*[R1C1]/(Kapp+[R1C1])+b). ∆F= fluorescence change; ∆Fmax= 
maximum fluorescence change; Kapp= apparent Kd; [R1C1] = R1C1 
concentration. For competition assays, 100nM of BHQ-R1C1 and varying 
concentrations of unlabeled HisSUMO-R1C1 were added to 250nM Alexa-ASD2. 
Samples were incubated for 1 hour and then read at 525nm (Figure 4.2D). To 
determine if non-specific quenching was being observed, 250nm of BHQ-GST or 
BHQ-ASD2 was incubated for an hour with varying concentrations of Alexa 488-
HisSUMO or Alexa-R1C1 (Figure 4.3A and B). 
 
4.5.10 Size exclusion chromatography 
 
BHQ-ASD2 and Alexa 488-R1C1 were fractionated by size exclusion 
chromatography over a Superose 6 HR10/30 column (GE Healthcare) 
equilibrated and run in PBS with 300mM NaCl. Eluted fractions containing the 
protein peak were subjected to SDS-PAGE followed by detection using GelCode 
Blue (Pierce).  
 
4.5.11 ELISA assay, detection methods, and affinity determination  
 
For the anti-SUMO detection system (Figure 4.3B), 1µg of GST or GST-
ASD2 diluted in 75µL PBS was immobilized for 16 hours at 4°C on 96-well 
Immulon 2B high binding plates (Thermo Scientific). Plates were blocked for 1 
hour at 25°C in 200µL SuperBlock T20 (TBS) Blocking buffer (Thermo Scientific). 
0.1µg, 1µg, and 10µg HisSUMO-R2C1 was added to wells in 40µL TBS-1 (20mM 
Tris HCl, 150mM KCl, 0.5% Triton X-100, pH 7.9) with 0.5% Bovine Serum 
Albumin (BSA) for 1 hour at 25°C. Unbound protein was removed with 4 washes 
in TBS-2 (20mM Tris HCl, 300mM KCl, 0.5% Triton X-100, pH 7.9). Anti-SUMO 
antibody was added at a dilution of 1:1000 in 40µL TBS-3 (25mM Tris HCl, 
8.25mM Tris Base, 154mM NaCl, 2% BSA, 0.05% Tween-20) for 1 hour at 25°C. 
Excess SUMO antibody was removed with 2 washes in TBS-T (25mM Tris HCl, 
137mM NaCl, 2.7mM KCl, 0.1% Tween-20). Goat anti-rabbit IgG HRP (BioRad) 
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was added at a dilution of 1:1000 in 40µL TBS-3 for 1 hour at 25°C. Following 2 
washes in TBST, 40µL TMB substrate (Pierce) was added for 15 minutes and 
quenched with 40µL 0.18 M H2SO4. Absorbance was measured at 450 nm using 
a SpectraMax M5 microplate reader. 
For the biotin-avidin detection system (Figure 4.3C), the ELISA assay was 
performed as just described except that Biotin-R2C1 was used in place of 
HisSUMO-R2C1 and High Sensitive NeutrAvidin-HRP was added at a dilution of 
1:40,000 for 1 hour in TBS-3, followed by detection using TMB substrate. 
Apparent binding affinity (Kd) was determined by immobilizing 0.5 µg of 
GST-ASD2 or ASD2 on 96-well plates. Concentrations of Biotin-R2C1 were 
added from 0-1778 nM for a total of 11 concentration points. ELISA was 
performed as described for the biotin-avidin detection system. The Kd was 
calculated using GraphPad Prism 4.0 using a hyperbolic fit with a non-zero 
intercept (∆A=∆Amax*[R2C1]/(Kd+[R2C1]). ∆A= absorbance change; ∆Amax= 
maximum absorbance change; [R2C1]= R2C1 concentration. Competition 
ELISAs were performed as described above with 100 ng of Biotin-R2C1 being 
combined with varying concentrations of unlabeled R2C1 (0-10µg) followed by 
incubation on plates for 1 hour at 25°C. 
 
4.5.12 High-throughput primary screen and dose-response in the CCG 
 
The 20,000 Chemical Diversity Library (ChemDiv) was screened in the 
Center for Chemical Genomics at the University of Michigan. All reagent 
additions were performed using Thermo Labsystems Multidrop and plate washes 
were performed using Bio Tek EL406 washer/aspirator. 150 ng of ASD2 diluted 
in 20 µL PBS (pH, 7.4) was immobilized for 16 hours at 4°C on 384-well high-
binding plates (Perkin Elmer). Unbound protein was removed with 2-80µL 
washes of PBS (pH, 7.4). Plates were blocked for 1 hour at 25°C in 80µL 
SuperBlock T20 (TBS) Blocking buffer (Thermo Scientific), followed by 2-80µL 
washes of PBS (pH, 7.4).  20 µL of Buffer A (20mM Tris HCl, 150mM KCl, 0.05% 
Triton X-100, 0.5% BSA, pH 7.9) was added to all wells. 200 nL of compounds 
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were pin-tooled (one per well) into columns 3-22 resulting in a final concentration 
of 10 µM using the Biomex FX (Beckman). 200nL of DMSO was added to control 
columns 1-2 (negative control) and 23-24 (positive control). 5 µg of unlabeled 
R2C1 in 20µL of Buffer A was added to columns 23-24 as a positive control for 
inhibition. After 30 minutes at 25°C, 10 ng of Biotin-R2C1 in 10µL of Buffer A was 
added to all wells and incubated for 1 hour at 25°C. Unbound protein was 
removed with 3 washes in 80µL wash buffer (Buffer A supplemented with 300mM 
KCl and 0.5% Triton X-100).  40µL of 1:40,000 NeutrAvidin-HRP diluted in TBS-3 
was added to all wells and incubated for 45 minutes at 25°C. Plates were 
washed 3 times in 80µL TBS-T, followed by the addition of 20 µL of TMB 
substrate for 5 minutes. The TMB reaction was quenched with 20 µL 0.18 M 
H2SO4. Absorbance was measured at 450 nm using an automated PHERAstar 
plate reader (BMG Labs). Positive hits were defined as having a percent 
inhibition greater than 3 standard deviations (3SD) away from the mean of the 
negative control for inhibition. 
 
4.5.13 Dose response and hit selection criteria 
 
Dose-response confirmation (180 compounds) was performed following the 
ELISA screening platform. Compound dilutions of 100µM, 59.8µM, 35.9µM, 
21.5µM, 12.9µM, 7.69µM, 4.61µM, and 2.70µM were delivered using the 
Mosquito X1 (TTP Labtech) in duplicate. Compounds with at least 30% inhibition 
and a pAC50 of 3.5 were considered active (74 compounds). Compounds with 
greater than 22% promiscuity and less than 60% efficacy were removed. The 
application of these selection criteria resulted in 36 compounds. The IC50 values 
for Compounds A-F were calculated using GraphPad Prism 4.0 using nonlinear 
regression and the log (inhibitor) vs. response, variable slope equation. 
Clustering was performed using DataMiner by the Tripos algorithm OptiSim 
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5.1 Background and Significance 
 
The regenerative capacity in the injured adult mammalian CNS is limited, in 
part, by an inhibitory extracellular environment in which myelin associated 
inhibitors (MAIs) contribute. The primary focus of this body of work has been the 
identification of a signaling pathway downstream of MAIs organized by the 
scaffold protein POSH. Further, high-throughput screening was performed to 
identify chemicals with the potential to inhibit POSH complex function to promote 
axonal growth in the presence of MAIs.  
In this dissertation, we have defined a signaling pathway downstream of the 
PirB receptor upon activation by the MAIs, Nogo66 and MAG. The activity of the 
PirB associated phosphatase Shp2 is required to inhibit axon length and LZK 
was identified as a potential Shp2 substrate. LZK co-associates with POSH and, 
together with Shroom3 and ROCK, relays MAI-mediated growth inhibition. The 
identification of the POSH complex as a signaling component of MAI pathways 
has provided insight into MAI intracellular signaling mechanisms.  The POSH 
complex provides novel targets for therapeutics to enhance regeneration after 
injury or disease in the CNS. Additionally, by selectively inhibiting the function of 
the POSH complex, axon growth in the CNS may be promoted without disrupting 
other inhibitory signaling pathways, allowing for regeneration and maintenance of 





5.2 The POSH complex mediates MAI growth inhibition 
 
Our studies define a central role for the POSH complex in relaying process 
growth inhibition downstream of MAG and NogoA and their receptor PirB 
(Chapter 3, Figure 3.8). MAG and NogoA, along with OMgp have been termed 
prototypic myelin inhibitors as they are highly expressed and have been well 
characterized as inhibitory proteins within myelin [1]. All three MAIs associate 
with the receptor PirB and the POSH complex relays NogoA signaling through 
PirB (Chapter 2 and [2]. We demonstrated that POSH is downstream of MAG 
and NogoA, thus we predict OMgp is also signaling through the POSH complex. 
There are additional receptors for MAIs including NgR1 and NgR2, as well as the 
integrin receptors [3-5]. NgR1 is a high affinity receptor for all three MAIs, while 
NgR2 has only been shown to bind MAG [3, 5, 6]. The question can then be 
raised: Is the POSH complex only a scaffold for MAI signaling through the 
receptor PirB or is POSH a convergence point for all MAI receptors?  
NgR1 does not contain an intracellular domain and must associate with a 
co-receptor to mediate intracellular signaling (p75, LINGO1, or Taj/TROY) [7-9]. 
PirB has been shown to complex with p75 upon MAG stimulation to promote 
activation of Shp2 function [10]. As we have linked Shp2 to the POSH complex, it 
is possible that POSH may be also be downstream of p75 signaling and thus 
POSH could also mediate signals emanating from NgR1 when it is coupled to 
p75. Interestingly, studies in NgR1 null mice have shown that a combinatorial 
approach of removing NgR1and PirB facilitates more robust axon extension in 
the presence of crude myelin in cell culture [2]. Therefore, if POSH is indeed a 
convergence point for MAIs, blocking POSH function may be more productive 
than targeting multiple MAI receptors for enhancement of axon outgrowth after 
injury. 
In addition to the prototypical MAIs, there are other classes of growth 
inhibitory proteins present in the CNS: canonical axon guidance molecules (ex. 
semaphorins, ephrins, netrins) and chondroitin sulfate proteoglycans (CSPGs) 
[11]. Our laboratory has previously determined that reduction of Robo1 and 
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EphrinB2 function in P19 neurons results in enhanced axon length indicative of 
their function as negative regulators of axon length and our data suggests that 
they do not signal through the POSH complex [12]. Given these results, it is 
unlikely that POSH is functioning in all pathways. Rather, we propose that POSH 
is a convergence point for MAIs.  
 
5.3 The role of POSH as a scaffold protein 
 
POSH is a multi-domain scaffold protein [13]. As a scaffold POSH regulates 
many diverse biological functions from apoptosis, to membrane trafficking, and 
our studies define a role for POSH as a negative regulator of axon outgrowth [12, 
14-20]. Complex formation by scaffold proteins can regulate selectivity in 
pathways, shape signaling outputs, and achieve new functions for preexisting 
signaling proteins [21]. Thus, examining the role of POSH as a scaffold protein 
may provide additional insight into MAI signaling and regulation. 
One function of a scaffold protein is to promote spatial organization of a 
signaling complex to the desired location in the cell [21]. For example, in 
differentiated PC12 cells, POSH exhibits a widespread punctate pattern in 
neurites and the cell body [22]. Upon growth factor deprivation or camptothecin 
treatment to induce apoptosis, POSH localizes to the perinuclear region of the 
neuron to promote JNK followed by cJun activation [22]. The change in 
localization of POSH to the perinuclear region is hypothesized to facilitate the 
translocation of JNK into the nucleus to activate cJun.  The same rationale can 
be applied to the role of POSH as a mediator of growth inhibition. In the axon of 
neurons, the growth cone responds to extracellular cues and relays these signals 
to cytoskeletal components to promote or inhibit growth [23]. Thus, a model could 
be proposed where upon stimulation by a MAI, the POSH complex becomes 
localized at the growth cone and promotes cytoskeletal rearrangements leading 
to inhibition of growth. Furthermore, the POSH-associated protein Shroom3 
associates with actin, and promotes the localization of ROCK to sites of apical 
constriction in epithelial cells [24]. Therefore, it is possible that MAI stimulus 
136 
 
leads to Shroom3 promoting localization of POSH at the growth cone through 
Shroom’s association with the actin-myosin cytoskeleton. This dissertation did 
not address spatial organization of the POSH complex, and it will be of interest to 
determine if MAI signaling promotes changes in sub-cellular location of POSH 
and/or its associated proteins to facilitate its role as a negative regulator of axon 
length. Another hypothesis that was not addressed is whether MAIs induce 
changes in expression of POSH complex proteins, and this could be examined 
by looking at changes in mRNA or protein expression over time in the presence 
of MAIs. 
The formation of distinct protein complexes by POSH also suggests that 
regulation of POSH function via post-translational modifications may promote or 
inhibit complex formation, and subsequent biological pathways. For example, Akt 
regulates POSH’s apoptotic function. Akt2 associates with POSH through its third 
SH3 domain and disassembles the complex through phosphorylation of MLK3 
[25]. Additionally, Akt1 and Akt2 have been shown to promote phosphorylation of 
POSH in the Rac-binding domain preventing Rac association and subsequent 
activation of JNK [26]. Inactivation of PTEN and, subsequent activation of PI3K 
and Akt, promotes axon growth and facilitates regeneration after injury in retinal 
ganglion cells [27, 28]. Collectively, these studies raise the hypothesis that Akt 
may regulate the POSH complex by promoting disassembly. Therefore, the 
stimulation of Akt activity may promote axon regeneration on multiple levels: (1) 
directly regulating the POSH complex and (2) through its role in other growth-
promoting pathways.  
 
5.4 The role of POSH as an E3 ubiquitin ligase 
 
POSH contains six domains promoting protein-protein interaction: a RING 
domain, 4-SH3 domains, and an activated Rac binding domain.  Truncation 
mutations in POSH removing the RING domain and the 3rd and 4th SH3 domain 
reveal that these domains are crucial for mediating axon length regulation [12].  
Consistent with this, Shroom3 associates with POSH through the 3rd SH3. The 
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necessity of the RING domain is interesting. The RING domain gives POSH a 
function as an E3 ligase. E3 ligases promote ubiquitination by bringing E2 
ubiquitin conjugating enzymes in contact with substrates [29]. Ubiquitination 
results in the formation of an isopeptide bond between ubiquitin’s C-terminal 
glycine residue (G76) with a lysine residue on the target protein [30]. Ubiquitin 
can form poly-ubiquitin chains with diverse structures through G76-K linkages 
with one of seven lysine residues present in ubiquitin. K48 linkages have been 
typically associated with targeting substrates for degradation by the proteasome, 
while K63 linkages regulate protein-protein interactions, kinase activation, and 
protein trafficking[31].  In other biological systems, there is evidence that POSH 
is able to mediate ubiquitination of substrates, using both K48 and K63 linked 
ubiquitination [14, 17, 19, 20]. K63 ubiquitination of the protein Herp causes a 
change in localization from the trans Golgi network to the endoplasmic 
reticulum[20].  Collectively, these studies, together with our finding that the RING 
domain of POSH is required for regulating axon outgrowth, support the 
hypothesis that ubiquitination events are playing a role in MAI growth inhibition.   
There is no precedent in the literature for ubiquitination events regulating 
the current known POSH complex members supporting axon outgrowth 
inhibition, Shroom3, ROCK, or LZK. Performing in vitro ubiquitination 
experiments in the presence of POSH would address their potential for 
ubiquitination. However, a more biologically relevant question is whether MAI 
stimulation promotes K63 or K48 ubiquitination on POSH complex members. 
POSH-mediated ubiquitination may facilitate protein-protein interactions or target 
a substrate for proteosomal degradation to inhibit axon length.  
Recently, it has been shown that upon MAG stimulation, PirB and Shp2 
along with p75 bind to the tropomyosin receptor kinase B (TrkB) receptor and 
promote the dephosphorylation of TrkB after activation by BDNF stimulation. This 
study proposes a model where growth inhibition by MAG is due, in part, to the 
inactivation of growth-promoting pathways. It is unknown whether Nogo66 also 
induces association with and dephosphorylation of TrkB. However, TrkB 
receptors have been shown to be regulated by ubiquitination and the E3 ligase 
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responsible for TrkB ubiquitination has yet to be identified. The E3 ligase activity 
of POSH is required for the negative regulation of axon outgrowth, and therefore 
it raises the hypothesis that POSH could be facilitating ubiquitination of TrkB 
following activation by NogoA-PirB [12]. It would be interesting if inhibitory cues 
were regulating TrkB on multiple levels, dephosphorylation and ubiquitination, 
and further studies will need to be performed to investigate this hypothesis. 
 
5.5 Shp2 and ROCK function downstream of MAIs 
 
Our results suggest that Nogo66 activation of CGNs results in an 
enhanced Shp2 trapping of multiple tyrosine phosphorylated proteins (Chapter 3, 
Figure 3.2). The identity of these proteins has yet to be determined, although as 
stated above Shp2 is linked to TrkB regulation, therefore TrkB is likely to be 
trapped by Shp2 in response to MAIs. Additionally, Shp2 also dephosphorylates 
ROCK, providing another link from Shp2 to the POSH complex. In a myeloid 
leukemia cell line, ROCKII is negatively regulated by tyrosine phosphorylation to 
promote cell adhesion. Shp2 dephosphorylates ROCKII, promoting its activation, 
and the deadhesion of cells [32]. Further, ROCK has previously been linked to 
MAI signaling as the ROCK antagonist, Y-27632, can promote neurite growth on 
MAI substrates in vitro and enhanced regeneration in rats subjected to 
corticospinal tract transection [33-35]. Additionally, our studies show that the 
association of ROCK and Shroom3 is crucial for axon length regulation. 
Collectively, these studies raise the hypothesis that Shp2 dephosphorylation of 
ROCK may be regulating its activity or association into the POSH-Shroom3 
complex downstream of MAI activation. 
Investigation into the molecular mechanism of ROCK signaling 
downstream of MAIs revealed that upon NogoA stimulation ROCK translocates 
to the cellular membrane and phosphorylation of myosin light chain is enhanced 
[36].  As stated previously, phosphorylation of MLC regulates myosin II function 
by promoting its interaction with actin, thereby activating myosin ATPase and 
enhancing cell contractility [37-39]. Additionally, ROCK can regulate actin 
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dynamics and microtubule stability through activation of LIM kinases and 
collapsing response mediator protein-2 (CRMP2), a neuronal protein that is 
involved in growth cone collapse [40, 41]. Therefore, it will be interesting to 
determine if association with POSH and Shroom3 promote ROCK’s activity on 
these substrates. Shroom3 associates with F-actin through its ASD1 domain and 
regulates myosin II function through its ASD2 domain [24, 42]. Thus, it is possible 
that Shroom3 may act as a scaffold protein tethering together the actin-myosin 
cytoskeleton with ROCK to promote efficient MAI signaling.  
Lastly, ROCK and RhoA, the upstream activator of ROCK, have been 
implicated in multiple inhibitory pathways such as chondroitin sulfate 
proteoglycans, semaphorin, ephrin, and repulsive guidance molecule (RGMa) 
[33, 34, 36, 43-45]. These findings highlight the complexity and redundancy of 
signaling molecules downstream of inhibitory cues. Thus, regulation or blocking 
unique protein-protein interactions, distinct for each signaling pathway, such as 
scaffold proteins, may provide more selective regeneration in the CNS. 
 
5.6 The role of Shp2 in POSH dependent MAI-mediated growth inhibition 
 
In these studies, we show that the phosphatase activity of Shp2 is required 
to regulate axonal outgrowth and mediate inhibitory signals from Nogo66 
downstream of the receptor PirB (Chapter 3, Figure 3.1). Ectopic expression of 
Shp2 is not able to suppress the POSH and LZK RNAi phenotype, suggesting 
that Shp2 is upstream of the POSH complex or it is regulating a protein at the 
same level as the complex (Figure 3.1). Collectively, these results indicated that 
Shp2 may be dephosphorylating a member of the POSH complex to inhibit axon 
outgrowth. Consistent with this hypothesis, we found that LZK is trapped by Shp2 
and Nogo66 stimulation promotes this association (Chapter 3, Figure 3.2).  
LZK is a member of the mixed-lineage kinase family whose activity is 
facilitated by dimerization and association with POSH. To our knowledge, 
regulation of LZK activity by phosphorylation has not been shown and these 
results raised several hypotheses as to the effect of phosphorylation events on 
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LZK in axon outgrowth regulation. Phosphorylation of LZK may be preventing 
dimer formation and thereby impeding its activation. Additionally, phosphorylation 
may prevent LZK association with POSH, preventing an active POSH signaling 
module. Therefore, our proposed model is that NogoA activation of the receptor 
PirB facilitates Shp2 phosphatase activity on LZK allowing correct formation of 
the POSH complex and/or promotes LZK kinase activity to mediate axon growth 
inhibition. This hypothesis also supports a secondary theory that growth-
promoting pathways induce phosphorylation of LZK, thereby negatively 
regulating the function of LZK as an inhibitor of axon length. 
 
5.7 The DLK conundrum 
 
Our studies suggest a role for DLK as a negative regulator of axon length 
and a mediator of NogoA growth inhibition (Chapter 3, Figure 3.4B). However, 
only LZK is trapped by Shp2 and signals downstream from PirB (Chapter 3, 
Figure 7). One hypothesis for this distinction between the kinases is that Shp2 
regulation is promoting the selection of LZK rather than DLK to relay Nogo66 
signaling through PirB. Elucidation of the mechanisms promoting phosphorylation 
events of LZK may provide insight into the differences between the kinases. 
Another possibility is that DLK is relaying MAI signaling through another receptor, 
such as NgR1.  
 
5.8 Promoting regeneration through POSH complex inhibition 
 
In these studies, we have shown that the POSH complex is downstream of 
NogoA, MAG, and PirB-mediated growth inhibition (Chapter 3, Figure 3.8). Thus, 
we hypothesized that small molecule inhibitors of the POSH complex formation 
would circumvent NogoA or MAG-mediated growth inhibition to promote 
regeneration of the injured CNS. To begin to address this hypothesis we 
performed a high-throughput screen to identify chemical inhibitors of the 
Shroom3-ROCK interaction. We have identified 36 potentially active molecules 
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and will test these molecules in primary neuronal cells for their ability to promote 
growth over NogoA or MAG (Chapter 4, Figure 4.7A). Due to POSH promoting 
the formation of a multi-protein complex, there are additional protein-protein 
interactions that could be tested. Inhibiting the direct association of Shroom3 and 
POSH was decided against due to the binding occurring through an SH3 domain, 
which may be of low affinity and contain a large, flat binding surface which may 
be difficult to inhibit with small molecules. However, blocking LZK function may 
be an ideal target for inhibition. Our laboratory has shown its kinase activity and 
association with POSH is required for process length and MAI growth inhibition 
(Chapter 2, Figures 2.1 and 2.7 and [15]). Thus, chemical inhibitors which block 
the ability of LZK to dimerize and subsequently activate or associate with POSH 
could be valuable tools to investigate growth inhibition mediated by the POSH 
complex. 
Extrinsic inhibitory proteins are only one factor limiting regeneration of the 
CNS, as a lack of intrinsic growth-promoting factors and a robust immunological 
response after injury also impedes CNS recovery [11, 46, 47]. Chondroitin sulfate 
proteoglycans (CSPGs) are basally present and upregulated by astrocytes after 
CNS damage and are both membrane bound and secreted into the extracellular 
space [48-50]. CSPGs can be cleaved with the bacterial enzyme Chondroitinase 
ABC and administering this enzyme promotes growth in the presence of CSPGs 
in cell culture and enhances functional recovery after spinal cord injury [51, 52]. 
Therefore, using a combination of chemical inhibitors which target MAI signaling 
and block CSPG function may be more efficacious. Additionally, chemicals that 
promote intrinsic growth, such as inhibitors of PTEN to promote mTOR 
activation, might also be beneficial in combination with MAIs [27, 53, 54].  As we 
continue to characterize the adult mammalian CNS, new and enhanced 






5.9 Concluding remarks 
 
In the past thirty years, there has been an explosion in our understanding of 
brain plasticity. The canonical model of the CNS as a stable and static structure 
has been modified to one that is more dynamic, but yet more controlled when 
compared directly to the developing CNS.  It is now acknowledged that to 
robustly regenerate the injured CNS a combinatorial strategy will need to be 
employed to target extrinsic inhibitory molecules and enhance intrinsic growth 
properties of neurons. Additionally, a goal of therapeutics for CNS injury is to 
promote the correct amount of regeneration without disrupting the connectivity of 
uninjured brain regions.  Towards this aim, this dissertation has identified the 
POSH complex as a novel target for therapeutics downstream of MAIs. By 
selectively inhibiting the POSH complex, axon outgrowth in the CNS may be 
promoted without disrupting other inhibitory signaling pathways, such as those 
required for maintaining uninjured neuronal connections, suggesting that fully 
characterizing inhibitory signaling pathways in the intact CNS is important for 
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